Document:

Centagenetix, Inc. 2001 Employee, Director and Consultant Stock Plan

 Exhibit 10.4 
 CENTAGENETIX, INC. 
 2001 EMPLOYEE,
DIRECTOR AND CONSULTANT STOCK PLAN 
 ADOPTED
ON AUGUST 25, 2001 

 TABLE OF CONTENTS 
  

							
	 1.
	 		 	DEFINITIONS.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . . . . . . .	  	1
				
	 2.
	 		 	PURPOSES OF THE
PLAN.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . 	  	3
				
	 3.
	 		 	SHARES SUBJECT TO THE
PLAN.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 	  	3
				
	 4.
	 		 	ADMINISTRATION OF THE
PLAN.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 .	  	3
				
	 5.
	 		 	ELIGIBILITY FOR
PARTICIPATION.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 .	  	4
				
	 6.
	 		 	TERMS AND CONDITIONS OF
OPTIONS.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . . . . . . . . . . . . . . .	  	4
				
		 	A.	 	    NON-QUALIFIED
OPTIONS  . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . .	  	4
		 	B.	 	    ISOS  . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 .	  	5
				
	 7.
	 		 	TERMS AND CONDITIONS OF STOCK
GRANTS.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . . . . . . . .	  	6
				
	 8.
	 		 	EXERCISE OF OPTIONS AND ISSUE OF
SHARES.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . . . . . . .	  	7
				
	 9.
	 		 	ACCEPTANCE OF STOCK GRANT AND ISSUE OF
SHARES.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . .	  	8
				
	 10.
	 		 	RIGHTS AS A
SHAREHOLDER.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . .	  	9
				
	 11.
	 		 	ASSIGNABILITY AND TRANSFERABILITY OF STOCK
RIGHTS.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . 	  	9
				
	 12.
	 		 	EFFECT ON OPTIONS OF TERMINATION OF SERVICE OTHER THAN FOR “CAUSE” OR DEATH OR
DISABILITY.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . . . . . . 	  	9
				
	 13.
	 		 	EFFECT ON OPTIONS OF TERMINATION OF SERVICE FOR
“CAUSE”.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . .	  	10
				
	 14.
	 		 	EFFECT ON OPTIONS OF TERMINATION OF SERVICE FOR
DISABILITY.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . .	  	11
				
	 15.
	 		 	EFFECT ON OPTIONS OF DEATH WHILE AN EMPLOYEE, DIRECTOR OR
CONSULTANT.  . . . . . . . . . . . . . .	  	11
				
	 16.
	 		 	EFFECT OF TERMINATION OF SERVICE ON STOCK
GRANTS.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . .	  	12
				
	 17.
	 		 	EFFECT ON STOCK GRANTS OF TERMINATION OF SERVICE OTHER THAN FOR “CAUSE” OR DEATH OR
DISABILITY.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . . .	  	12
				
	 18.
	 		 	PURCHASE FOR
INVESTMENT.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . 	  	12
				
	 19.
	 		 	DISSOLUTION OR LIQUIDATION OF THE
COMPANY.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . .	  	13
				
	 20.
	 		 	ADJUSTMENTS.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . . . . .	  	13
				
		 	A.	 	    STOCK DIVIDENDS AND STOCK
SPLITS.  . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . .	  	13
		 	B.	 	    CONSOLIDATIONS OR
MERGERS.  . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . 	  	14
		 	C.	 	    RECAPITALIZATION OR
REORGANIZATION.  . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 	  	14
		 	D.	 	    MODIFICATION OF
ISOS.  . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . .	  	15
				
	 21.
	 		 	ISSUANCES OF
SECURITIES.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . .	  	15

							
	 22.
	 		 	FRACTIONAL
SHARES.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . .	  	15
				
	 23.
	 		 	CONVERSION OF ISOS INTO NON-QUALIFIED OPTIONS; TERMINATION OF
ISOS.  . . . . . . . . . . . . . . . . . . . .	  	15
				
	 24.
	 		 	WITHHOLDING.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . . . . .	  	16
				
	 25.
	 		 	NOTICE TO COMPANY OF DISQUALIFYING
DISPOSITION.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . .	  	16
				
	 26.
	 		 	TERMINATION OF THE
PLAN.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . 	  	16
				
	 27.
	 		 	AMENDMENT OF THE PLAN AND
AGREEMENTS.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . . . . . .	  	17
				
	 28.
	 		 	EMPLOYMENT OR OTHER
RELATIONSHIP.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . . . . . . . . . . . 	  	17
				
	 29.
	 		 	GOVERNING
LAW.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . 	  	17

  

 ii 

 CENTAGENETIX, INC. 
 2001 EMPLOYEE, DIRECTOR AND CONSULTANT STOCK PLAN 
  

	1.	DEFINITIONS. 

 Unless otherwise specified or unless
the context otherwise requires, the following terms, as used in this Centagenetix, Inc. 2001 Employee, Director and Consultant Stock Plan, have the following meanings: 
 Administrator means the Board of Directors, unless it has delegated power to act on its behalf to the Committee, in which case the Administrator means the Committee. 
 Affiliate means a corporation which, for purposes of Section 424 of the Code, is a parent or subsidiary of the Company, direct or indirect.

 Board of Directors means the Board of Directors of the Company. 
 Code means the United States Internal Revenue Code of 1986, as amended. 
 Committee means the committee of the Board of Directors to which the Board of Directors has delegated power to act under or pursuant to the
provisions of the Plan. 
 Common Stock means shares of the Company’s common stock, $.001 par value per share. 
 Company means Centagenetix, Inc., a Delaware corporation. 
 Disability or Disabled means permanent and total disability as defined in Section 22(e)(3) of the Code. 
 Fair Market Value of a Share of Common Stock means: 
 (1) If the Common Stock is listed on a national
securities exchange or traded in the over-the-counter market and sales prices are regularly reported for the Common Stock, the closing or last price of the Common Stock on the Composite Tape or other comparable reporting system for the trading day
immediately preceding the applicable date; 
 (2) If the Common Stock is not traded on a national securities exchange but is traded on the
over-the-counter market, if sales prices are not regularly reported for the Common Stock for the trading day referred to in clause (1), and if bid and 

 
asked prices for the Common Stock are regularly reported, the mean between the bid and the asked price for the Common Stock at the close of trading in the
over-the-counter market for the trading day on which Common Stock was traded immediately preceding the applicable date; and 
 (3) If the
Common Stock is neither listed on a national securities exchange nor traded in the over-the-counter market, such value as the Administrator, in good faith, shall determine. 
 ISO means an option meant to qualify as an incentive stock option under Section 422 of the Code. 
 Key Employee means an employee of the Company or of an Affiliate (including, without limitation, an employee who is also serving as an officer or
director of the Company or of an Affiliate), designated by the Administrator to be eligible to be granted one or more Stock Rights under the Plan. 
 Non-Qualified Option means an option which is not intended to qualify as an ISO. 
 Option means an ISO or
Non-Qualified Option granted under the Plan. 
 Option Agreement means an agreement between the Company and a Participant delivered
pursuant to the Plan, in such form as the Administrator shall approve. 
 Participant means a Key Employee, director or consultant to
whom one or more Stock Rights are granted under the Plan. As used herein, “Participant” shall include “Participant’s Survivors” where the context requires. 
 Plan means this Centagenetix, Inc. 2001 Employee, Director and Consultant Stock Plan. 
 Shares means shares of the Common Stock as to which Stock Rights have been or may be granted under the Plan or any shares of capital stock into
which the Shares are changed or for which they are exchanged within the provisions of Paragraph 3 of the Plan. The Shares issued under the Plan may be authorized and unissued shares or shares held by the Company in its treasury, or both.

 Stock Grant means a grant by the Company of Shares under the Plan. 
 Stock Grant Agreement means an agreement between the Company and a Participant delivered pursuant to the Plan, in such form as the Administrator
shall approve. 
 Stock Right means a right to Shares of the Company granted pursuant to the Plan, such as an ISO, a Non-Qualified
Option or a Stock Grant. 
  

 2 

 Survivors means a deceased Participant’s legal representatives and/or any person or persons
who acquired the Participant’s rights to a Stock Right by will or by the laws of descent and distribution. 
  

	2.	PURPOSES OF THE PLAN. 

 The Plan is intended to
encourage ownership of Shares by Key Employees and directors of and certain consultants to the Company in order to attract such people, to induce them to work for the benefit of the Company or of an Affiliate and to provide additional incentive for
them to promote the success of the Company or of an Affiliate. The Plan provides for the granting of ISOs, Non-Qualified Options and Stock Grants. 
  

	3.	SHARES SUBJECT TO THE PLAN. 

 The number of Shares
which may be issued from time to time pursuant to this Plan shall be 1,525,120 * shares of Common Stock or the equivalent of such number of Shares after the Administrator, in its sole discretion, has interpreted the effect of any stock split, stock
dividend, combination, recapitalization or similar transaction in accordance with Paragraph 20 of the Plan. 
 If an Option ceases to be
“outstanding”, in whole or in part, or if the Company shall reacquire any Shares issued pursuant to a Stock Grant, the Shares which were subject to such Option and any Shares so reacquired by the Company shall be available for the granting
of other Stock Rights under the Plan. Any Option shall be treated as “outstanding” until such Option is exercised in full, or terminates or expires under the provisions of the Plan, or by agreement of the parties to the pertinent Option
Agreement. 
 * - adjusted for pre-merger reverse stock split 
  

	4.	ADMINISTRATION OF THE PLAN. 

 The Administrator of
the Plan will be the Board of Directors, except to the extent the Board of Directors delegates its authority to the Committee, in which case the Committee shall be the Administrator. Subject to the provisions of the Plan, the Administrator is
authorized to: 
  

	 	a.	Interpret the provisions of the Plan or of any Option or Stock Grant and to make all rules and determinations which it deems necessary or advisable for the administration of the
Plan; 

  

	 	b.	Determine which employees of the Company or of an Affiliate shall be designated as Key Employees and which of the Key Employees, directors and consultants shall be granted Stock
Rights; 

  

 3 

	 	c.	Determine the number of Shares for which a Stock Right or Stock Rights shall be granted, provided, however, that in no event shall Stock Rights with respect to more than 750,000
shares be granted to any Participant in any fiscal year; and 

  

	 	d.	Specify the terms and conditions upon which a Stock Right or Stock Rights may be granted; 

 provided, however, that all such interpretations, rules, determinations, terms and conditions shall be made and prescribed in the context of preserving the tax status under Section 422 of the Code of those
Options which are designated as ISOs. Subject to the foregoing, the interpretation and construction by the Administrator of any provisions of the Plan or of any Stock Right granted under it shall be final, unless otherwise determined by the Board of
Directors, if the Administrator is the Committee. 
  

	5.	ELIGIBILITY FOR PARTICIPATION. 

 The Administrator
will, in its sole discretion, name the Participants in the Plan, provided, however, that each Participant must be a Key Employee, director or consultant of the Company or of an Affiliate at the time a Stock Right is granted. Notwithstanding the
foregoing, the Administrator may authorize the grant of a Stock Right to a person not then an employee, director or consultant of the Company or of an Affiliate; provided, however, that the actual grant of such Stock Right shall be conditioned upon
such person becoming eligible to become a Participant at or prior to the time of the delivery of the Stock Grant Agreement evidencing such Stock Right. ISOs may be granted only to Key Employees. Non-Qualified Options and Stock Grants may be granted
to any Key Employee, director or consultant of the Company or an Affiliate. The granting of any Stock Right to any individual shall neither entitle that individual to, nor disqualify him or her from, participation in any other grant of Stock Rights.

  

	6.	TERMS AND CONDITIONS OF OPTIONS. 

 Each Option shall
be set forth in writing in an Option Agreement, duly executed by the Company and, to the extent required by law or requested by the Company, by the Participant. The Administrator may provide that Options be granted subject to such terms and
conditions, consistent with the terms and conditions specifically required under this Plan, as the Administrator may deem appropriate including, without limitation, subsequent approval by the shareholders of the Company of this Plan or any
amendments thereto. 
  

	 	A.	Non-Qualified Options: Each Option intended to be a Non-Qualified Option shall be subject to the terms and conditions which the Administrator determines to be appropriate and
in the best interest of the Company, subject to the following minimum standards for any such Non-Qualified Option: 

  

	 	a.	Option Price: Each Option Agreement shall state the option price (per share) of the Shares covered by each Option, which option price shall be determined by the Administrator but
shall not be less than the par value per share of Common Stock. 

  

 4 

	 	b.	Each Option Agreement shall state the number of Shares to which it pertains; 

  

	 	c.	Each Option Agreement shall state the date or dates on which it first is exercisable and the date after which it may no longer be exercised, and may provide that the Option rights
accrue or become exercisable in installments over a period of months or years, or upon the occurrence of certain conditions or the attainment of stated goals or events; and 

  

	 	d.	Exercise of any Option may be conditioned upon the Participant’s execution of a Share purchase agreement in form satisfactory to the Administrator providing for certain
protections for the Company and its other shareholders, including requirements that: 

  

	 	i.	The Participant’s or the Participant’s Survivors’ right to sell or transfer the Shares may be restricted; and 

  

	 	ii.	The Participant or the Participant’s Survivors may be required to execute letters of investment intent and must also acknowledge that the Shares will bear legends noting any
applicable restrictions. 

  

	 	B.	ISOs: Each Option intended to be an ISO shall be issued only to a Key Employee and be subject to at least the following terms and conditions, with such additional
restrictions or changes as the Administrator determines are appropriate but not in conflict with Section 422 of the Code and relevant regulations and rulings of the Internal Revenue Service: 

  

	 	a.	Minimum standards: The ISO shall meet the minimum standards required of Non-Qualified Options, as described in Paragraph 6(A) above, except clause (a) thereunder.

  

	 	b.	Option Price: Immediately before the Option is granted, if the Participant owns, directly or by reason of the applicable attribution rules in Section 424(d) of the Code:

  

	 	i.	Ten percent (10%) or less of the total combined voting power of all classes of stock of the Company or an Affiliate, the Option price per share of the Shares covered by
each Option shall not be less than one hundred percent (100%) of the Fair Market Value per share of the Shares on the date of the grant of the Option. 

  

 5 

	 	ii.	More than ten percent (10%) of the total combined voting power of all classes of stock of the Company or an Affiliate, the Option price per share of the Shares covered by each
Option shall not be less than one hundred ten percent (110%) of the said Fair Market Value on the date of grant. 

  

	 	c.	Term of Option: For Participants who own 

  

	 	i.	Ten percent (10%) or less of the total combined voting power of all classes of stock of the Company or an Affiliate, each Option shall terminate not more than ten
(10) years from the date of the grant or at such earlier time as the Option Agreement may provide. 

  

	 	ii.	More than ten percent (10%) of the total combined voting power of all classes of stock of the Company or an Affiliate, each Option shall terminate not more than five
(5) years from the date of the grant or at such earlier time as the Option Agreement may provide. 

  

	 	d.	Limitation on Yearly Exercise: The Option Agreements shall restrict the amount of Options which may be exercisable in any calendar year (under this or any other ISO plan of the
Company or an Affiliate) so that the aggregate Fair Market Value (determined at the time each ISO is granted) of the stock with respect to which ISOs are exercisable for the first time by the Participant in any calendar year does not exceed one
hundred thousand dollars ($100,000), provided that this subparagraph (d) shall have no force or effect if its inclusion in the Plan is not necessary for Options issued as ISOs to qualify as ISOs pursuant to Section 422(d) of the Code.

  

	7.	TERMS AND CONDITIONS OF STOCK GRANTS. 

 Each offer
of a Stock Grant to a Participant shall state the date prior to which the Stock Grant must be accepted by the Participant, and the principal terms of each Stock Grant shall be set forth in a Stock Grant Agreement, duly executed by the Company and,
to the extent required by law or requested by the Company, by the Participant. The Stock Grant Agreement shall be in a form approved by the Administrator and shall contain terms and conditions which the Administrator determines to be appropriate and
in the best interest of the Company, subject to the following minimum standards: 
  

	 	(a)	Each Stock Grant Agreement shall state the purchase price (per share), if any, of the Shares covered by each Stock Grant, which purchase price shall be determined by the
Administrator but shall not be less than the minimum consideration required by the Delaware Law on the date of the grant of the Stock Grant; 

  

 6 

	 	(b)	Each Stock Grant Agreement shall state the number of Shares to which the Stock Grant pertains; and 

  

	 	(c)	Each Stock Grant Agreement shall include the terms of any right of the Company to reacquire the Shares subject to the Stock Grant, including the time and events upon which such
rights shall accrue and the purchase price therefor, if any. 

  

	8.	EXERCISE OF OPTIONS AND ISSUE OF SHARES. 

 An Option
(or any part or installment thereof) shall be exercised by giving written notice to the Company at its principal executive office address, together with provision for payment of the full purchase price in accordance with this Paragraph for the
Shares as to which the Option is being exercised, and upon compliance with any other condition(s) set forth in the Option Agreement. Such written notice shall be signed by the person exercising the Option, shall state the number of Shares with
respect to which the Option is being exercised and shall contain any representation required by the Plan or the Option Agreement. Payment of the purchase price for the Shares as to which such Option is being exercised shall be made (a) in
United States dollars in cash or by check, or (b) at the discretion of the Administrator, through delivery of shares of Common Stock having a Fair Market Value equal as of the date of the exercise to the cash exercise price of the Option, or
(c) at the discretion of the Administrator, by having the Company retain from the shares otherwise issuable upon exercise of the Option, a number of shares having a Fair Market Value equal as of the date of exercise to the exercise price of the
Option, or (d) at the discretion of the Administrator, by delivery of the grantee’s personal recourse note bearing interest payable not less than annually at no less than 100% of the applicable federal rate, as defined in
Section 1274(d) of the Code, or (e) at the discretion of the Administrator, in accordance with a cashless exercise program established with a securities brokerage firm, and approved by the Administrator, or (f) at the discretion of
the Administrator, by any combination of (a), (b), (c), (d) and (e) above. Notwithstanding the foregoing, the Administrator shall accept only such payment on exercise of an ISO as is permitted by Section 422 of the Code. 

The Company shall then reasonably promptly deliver the Shares as to which such Option was exercised to the Participant (or to the Participant’s
Survivors, as the case may be). In determining what constitutes “reasonably promptly,” it is expressly understood that the issuance and delivery of the Shares may be delayed by the Company in order to comply with any law or regulation
(including, without limitation, state securities or “blue sky” laws) which requires the Company to take any action with respect to the Shares prior to their issuance. The Shares shall, upon delivery, be evidenced by an appropriate
certificate or certificates for fully paid, non-assessable Shares. 
 The Administrator shall have the right to accelerate the date of
exercise of any installment of any Option; provided that the Administrator shall not accelerate the exercise date of any installment of any Option granted to any Key Employee as an ISO (and not previously converted into a Non-Qualified Option
pursuant to Paragraph 23) if such acceleration would violate the annual vesting limitation contained in Section 422(d) of the Code, as described in Paragraph 6.B.d. 
  

 7 

 The Administrator may, in its discretion, amend any term or condition of an outstanding Option provided
(i) such term or condition as amended is permitted by the Plan, (ii) any such amendment shall be made only with the consent of the Participant to whom the Option was granted, or in the event of the death of the Participant, the
Participant’s Survivors, if the amendment is adverse to the Participant, and (iii) any such amendment of any ISO shall be made only after the Administrator, after consulting the counsel for the Company, determines whether such amendment
would constitute a “modification” of any Option which is an ISO (as that term is defined in Section 424(h) of the Code) or would cause any adverse tax consequences for the holder of such ISO. 
  

	9.	ACCEPTANCE OF STOCK GRANT AND ISSUE OF SHARES. 

 A
Stock Grant (or any part or installment thereof) shall be accepted by executing the Stock Grant Agreement and delivering it to the Company at its principal office address, together with provision for payment of the full purchase price, if any, in
accordance with this Paragraph for the Shares as to which such Stock Grant is being accepted, and upon compliance with any other conditions set forth in the Stock Grant Agreement. Payment of the purchase price for the Shares as to which such Stock
Grant is being accepted shall be made (a) in United States dollars in cash or by check, or (b) at the discretion of the Administrator, through delivery of shares of Common Stock having a fair market value equal as of the date of acceptance
of the Stock Grant to the purchase price of the Stock Grant determined in good faith by the Administrator, or (c) at the discretion of the Administrator, by delivery of the grantee’s personal recourse note bearing interest payable not less
than annually at no less than 100% of the applicable federal rate, as defined in Section 1274(d) of the Code, or (d) at the discretion of the Administrator, by any combination of (a), (b) and (c) above. 
 The Company shall then reasonably promptly deliver the Shares as to which such Stock Grant was accepted to the Participant (or to the Participant’s
Survivors, as the case may be), subject to any escrow provision set forth in the Stock Grant Agreement. In determining what constitutes “reasonably promptly,” it is expressly understood that the issuance and delivery of the Shares may be
delayed by the Company in order to comply with any law or regulation (including, without limitation, state securities or “blue sky” laws) which requires the Company to take any action with respect to the Shares prior to their issuance.

 The Administrator may, in its discretion, amend any term or condition of an outstanding Stock Grant or Stock Grant Agreement provided
(i) such term or condition as amended is permitted by the Plan, and (ii) any such amendment shall be made only with the consent of the Participant to whom the Stock Grant was made, if the amendment is adverse to the Participant.

  

 8 

	10.	RIGHTS AS A SHAREHOLDER. 

 No Participant to whom a
Stock Right has been granted shall have rights as a shareholder with respect to any Shares covered by such Stock Right, except after due exercise of the Option or acceptance of the Stock Grant and tender of the full purchase price, if any, for the
Shares being purchased pursuant to such exercise or acceptance and registration of the Shares in the Company’s share register in the name of the Participant. 
  

	11.	ASSIGNABILITY AND TRANSFERABILITY OF STOCK RIGHTS. 

 By its terms, a Stock Right granted to a Participant shall not be transferable by the Participant other than (i) by will or by the laws of descent and distribution, or (ii) as otherwise determined by the Administrator and set
forth in the applicable Option Agreement or Stock Grant Agreement. The designation of a beneficiary of a Stock Right by a Participant shall not be deemed a transfer prohibited by this Paragraph. Except as provided above, a Stock Right shall only be
exercisable or may only be accepted, during the Participant’s lifetime, by such Participant (or by his or her legal representative) and shall not be assigned, pledged or hypothecated in any way (whether by operation of law or otherwise) and
shall not be subject to execution, attachment or similar process. Any attempted transfer, assignment, pledge, hypothecation or other disposition of any Stock Right or of any rights granted thereunder contrary to the provisions of this Plan, or the
levy of any attachment or similar process upon a Stock Right, shall be null and void. 
  

	12.	EFFECT ON OPTIONS OF TERMINATION OF SERVICE OTHER THAN FOR “CAUSE” OR DEATH OR DISABILITY. 

 Except as otherwise provided in the pertinent Option Agreement in the event of a termination of service (whether as an employee, director or consultant)
with the Company or an Affiliate before the Participant has exercised an Option, the following rules apply: 
  

	 	a.	A Participant who ceases to be an employee, director or consultant of the Company or of an Affiliate (for any reason other than termination for “cause”, Disability, or
death for which events there are special rules in Paragraphs 13, 14, and 15, respectively), may exercise any Option granted to him or her to the extent that the Option is exercisable on the date of such termination of service, but only within such
term as the Administrator has designated in the pertinent Option Agreement. 

  

	 	b.	Except as provided in Subparagraph (c) below, or Paragraph 14 or 15, in no event may an Option Agreement provide, if an Option is intended to be an ISO, that the time for
exercise be later than three (3) months after the Participant’s termination of employment. 

  

 9 

	 	c.	The provisions of this Paragraph, and not the provisions of Paragraph 14 or 15, shall apply to a Participant who subsequently becomes Disabled or dies after the termination of
employment, director status or consultancy, provided, however, in the case of a Participant’s Disability or death within three (3) months after the termination of employment, director status or consultancy, the Participant or the
Participant’s Survivors may exercise the Option within one (1) year after the date of the Participant’s termination of employment, but in no event after the date of expiration of the term of the Option. 

  

	 	d.	Notwithstanding anything herein to the contrary, if subsequent to a Participant’s termination of employment, termination of director status or termination of consultancy, but
prior to the exercise of an Option, the Board of Directors determines that, either prior or subsequent to the Participant’s termination, the Participant engaged in conduct which would constitute “cause”, then such Participant shall
forthwith cease to have any right to exercise any Option. 

  

	 	e.	A Participant to whom an Option has been granted under the Plan who is absent from work with the Company or with an Affiliate because of temporary disability (any disability other
than a permanent and total Disability as defined in Paragraph 1 hereof), or who is on leave of absence for any purpose, shall not, during the period of any such absence, be deemed, by virtue of such absence alone, to have terminated such
Participant’s employment, director status or consultancy with the Company or with an Affiliate, except as the Administrator may otherwise expressly provide. 

  

	 	f.	Except as required by law or as set forth in the pertinent Option Agreement, Options granted under the Plan shall not be affected by any change of a Participant’s status within
or among the Company and any Affiliates, so long as the Participant continues to be an employee, director or consultant of the Company or any Affiliate. 

  

	13.	EFFECT ON OPTIONS OF TERMINATION OF SERVICE FOR “CAUSE”. 

 Except as otherwise provided in the pertinent Option Agreement, the following rules apply if the Participant’s service (whether as an employee, director or consultant) with the Company or an Affiliate is
terminated for “cause” prior to the time that all his or her outstanding Options have been exercised: 
  

	 	a.	All outstanding and unexercised Options as of the time the Participant is notified his or her service is terminated for “cause” will immediately be forfeited.

  

	 	b.	 For purposes of this Plan, “cause” shall include (and is not limited to) dishonesty with respect to the Company or any Affiliate, insubordination,
substantial malfeasance or non-feasance of duty, unauthorized disclosure of confidential 

  

 10 

	 	 
information, and conduct substantially prejudicial to the business of the Company or any Affiliate. The determination of the Administrator as to the
existence of “cause” will be conclusive on the Participant and the Company. 

  

	 	c.	“Cause” is not limited to events which have occurred prior to a Participant’s termination of service, nor is it necessary that the Administrator’s finding of
“cause” occur prior to termination. If the Administrator determines, subsequent to a Participant’s termination of service but prior to the exercise of an Option, that either prior or subsequent to the Participant’s termination
the Participant engaged in conduct which would constitute “cause”, then the right to exercise any Option is forfeited. 

  

	 	d.	Any definition in an agreement between the Participant and the Company or an Affiliate, which contains a conflicting definition of “cause” for termination and which is in
effect at the time of such termination, shall supersede the definition in this Plan with respect to such Participant. 

  

	14.	EFFECT ON OPTIONS OF TERMINATION OF SERVICE FOR DISABILITY. 

 Except as otherwise provided in the pertinent Option Agreement, a Participant who ceases to be an employee, director or consultant of the Company or of an Affiliate by reason of Disability may exercise any Option granted to such
Participant, to the extent exercisable but not exercised on the date of Disability. 
 A Disabled Participant may exercise such rights only
within a period of not more than one (1) year after the date of the Participant’s termination of employment, directorship or consultancy, as the case may be, notwithstanding that the Participant might have been able to exercise the Option
as to some or all of the Shares on a later date if the Participant had not become disabled and had continued to be an employee, director or consultant or, if earlier, within the originally prescribed term of the Option. 
 The Administrator shall make the determination both of whether Disability has occurred and the date of its occurrence (unless a procedure for such
determination is set forth in another agreement between the Company and such Participant, in which case such procedure shall be used for such determination). If requested, the Participant shall be examined by a physician selected or approved by the
Administrator, the cost of which examination shall be paid for by the Company. 
  

	15.	EFFECT ON OPTIONS OF DEATH WHILE AN EMPLOYEE, DIRECTOR OR CONSULTANT. 

 Except as otherwise provided in the pertinent Option Agreement, in the event of the death of a Participant while the Participant is an employee, director or consultant of the Company or of an Affiliate, such Option
may be exercised by the Participant’s Survivors, to the extent exercisable but not exercised on the date of death. 
  

 11 

 If the Participant’s Survivors wish to exercise the Option, they must take all necessary steps to
exercise the Option within one (1) year after the date of death of such Participant, notwithstanding that the decedent might have been able to exercise the Option as to some or all of the Shares on a later date if he or she had not died and had
continued to be an employee, director or consultant or, if earlier, within the originally prescribed term of the Option. 
  

	16.	EFFECT OF TERMINATION OF SERVICE ON STOCK GRANTS. 

 In the event of a termination of service (whether as an employee, director or consultant) with the Company or an Affiliate for any reason before the Participant has accepted a Stock Grant, such offer shall terminate. 
 For purposes of this Paragraph 16 and Paragraph 17 below, a Participant to whom a Stock Grant has been offered under the Plan who is absent from work
with the Company or with an Affiliate because of temporary disability (any disability other than a permanent and total Disability as defined in Paragraph 1 hereof), or who is on leave of absence for any purpose, shall not, during the period of any
such absence, be deemed, by virtue of such absence alone, to have terminated such Participant’s employment, director status or consultancy with the Company or with an Affiliate, except as the Administrator may otherwise expressly provide.

 In addition, for purposes of this Paragraph 16 and Paragraph 17 below, any change of employment or other service within or among the
Company and any Affiliates shall not be treated as a termination of employment, director status or consultancy so long as the Participant continues to be an employee, director or consultant of the Company or any Affiliate; provided, however, any
change in the status of such Participant from an employee to a non-employee shall be treated as a termination. 
  

	17.	EFFECT ON STOCK GRANTS OF TERMINATION OF SERVICE OTHER THAN FOR “CAUSE” OR DEATH OR DISABILITY. 

 Except as otherwise provided in the pertinent Stock Grant Agreement, in the event of a termination of service (whether as an employee, director or
consultant), other than termination for “cause,” Disability, or death, respectively, before all Company rights of repurchase shall have lapsed, then the Company shall have the right to repurchase that number of Shares subject to a Stock
Grant as to which the Company’s repurchase rights have not lapsed. 
  

	18.	PURCHASE FOR INVESTMENT. 

 Unless the offering and
sale of the Shares to be issued upon the particular exercise or acceptance of a Stock Right shall have been effectively registered under the Securities Act of 

  

 12 

 
1933, as now in force or hereafter amended (the “1933 Act”), the Company shall be under no obligation to issue the Shares covered by such exercise
unless and until the following conditions have been fulfilled: 
  

	 	a.	The person(s) who exercise(s) or accept(s) such Stock Right shall warrant to the Company, prior to the receipt of such Shares, that such person(s) are acquiring such Shares for
their own respective accounts, for investment, and not with a view to, or for sale in connection with, the distribution of any such Shares, in which event the person(s) acquiring such Shares shall be bound by the provisions of the following legend
which shall be endorsed upon the certificate(s) evidencing their Shares issued pursuant to such exercise or such grant: 

 “The shares represented by this certificate have been taken for investment and they may not be sold or otherwise transferred by any person, including a pledgee, unless (1) either (a) a Registration Statement with respect to
such shares shall be effective under the Securities Act of 1933, as amended, or (b) the Company shall have received an opinion of counsel satisfactory to it that an exemption from registration under such Act is then available, and
(2) there shall have been compliance with all applicable state securities laws.” 
  

	 	b.	At the discretion of the Administrator, the Company shall have received an opinion of its counsel that the Shares may be issued upon such particular exercise or acceptance in
compliance with the 1933 Act without registration thereunder. 

  

	19.	DISSOLUTION OR LIQUIDATION OF THE COMPANY. 

 Upon
the dissolution or liquidation of the Company, all Options granted under this Plan which as of such date shall not have been exercised and all Stock Grants which have not been accepted will terminate and become null and void; provided, however, that
if the rights of a Participant or a Participant’s Survivors have not otherwise terminated and expired, the Participant or the Participant’s Survivors will have the right immediately prior to such dissolution or liquidation to exercise or
accept any Stock Right to the extent that the Stock Right is exercisable or subject to acceptance as of the date immediately prior to such dissolution or liquidation. 
  

	20.	ADJUSTMENTS. 

 Upon the occurrence of any of the
following events, a Participant’s rights with respect to any Stock Right granted to him or her hereunder shall be adjusted as hereinafter provided, unless otherwise specifically provided in the pertinent Option Agreement or Stock Grant
Agreement: 
 A. Stock Dividends and Stock Splits. If (i) the shares of Common Stock shall be subdivided or combined into a
greater or smaller number of shares or if the Company shall issue any shares of Common Stock as a stock dividend on its outstanding Common Stock, or (ii) additional shares or new or different shares or other securities of the Company or other
non-cash assets are distributed with respect to such shares of Common Stock, the number of shares of Common Stock deliverable upon the exercise or acceptance of such Stock Right may be appropriately increased or decreased proportionately, and
appropriate adjustments may be made in the purchase price per share to reflect such events. The number of Shares subject to the limitation in Paragraph 4(c) shall also be proportionately adjusted upon the occurrence of such events. 
  

 13 

 B. Consolidations or Mergers. If the Company is to be consolidated with or acquired by another
entity in a merger, sale of all or substantially all of the Company’s assets or otherwise (an “Acquisition”), the Administrator or the board of directors of any entity assuming the obligations of the Company hereunder (the
“Successor Board”), shall, as to outstanding Options, either (i) make appropriate provision for the continuation of such Options by substituting on an equitable basis for the Shares then subject to such Options either the
consideration payable with respect to the outstanding shares of Common Stock in connection with the Acquisition or securities of any successor or acquiring entity; or (ii) upon written notice to the Participants, provide that all Options must
be exercised (either to the extent then exercisable or, at the discretion of the Administrator, all Options being made fully exercisable for purposes of this Subparagraph B) at the end of which period the Options shall terminate; or
(iii) terminate all Options in exchange for a cash payment equal to the excess of the Fair Market Value of the Shares subject to such Options (either to the extent then exercisable or, at the discretion of the Administrator, all Options being
made fully exercisable for purposes of this Subparagraph B) over the exercise price thereof. 
 With respect to outstanding Stock Grants, the
Administrator or the Successor Board, shall either (i) make appropriate provisions for the continuation of such Stock Grants by substituting on an equitable basis for the Shares then subject to such Stock Grants either the consideration payable
with respect to the outstanding Shares of Common Stock in connection with the Acquisition or securities of any successor or acquiring entity; or (ii) upon written notice to the Participants, provide that all Stock Grants must be accepted (to
the extent then subject to acceptance) within a specified number of days of the date of such notice, at the end of which period the offer of the Stock Grants shall terminate; or (iii) terminate all Stock Grants in exchange for a cash payment
equal to the excess of the Fair Market Value of the Shares subject to such Stock Grants over the purchase price thereof, if any. In addition, in the event of an Acquisition, the Administrator may waive any or all Company repurchase rights with
respect to outstanding Stock Grants. 
 C. Recapitalization or Reorganization. In the event of a recapitalization or reorganization of
the Company (other than a transaction described in Subparagraph B above) pursuant to which securities of the Company or of another corporation are issued with respect to the outstanding shares of Common Stock, a Participant upon exercising or
accepting a Stock Right shall be entitled to receive for the purchase price, if any, paid upon such exercise or acceptance the securities which would have been received if such Stock Right had been exercised or accepted prior to such
recapitalization or reorganization. 
  

 14 

 D. Modification of ISOs. Notwithstanding the foregoing, any adjustments made pursuant to
Subparagraph A, B or C with respect to ISOs shall be made only after the Administrator, after consulting with counsel for the Company, determines whether such adjustments would constitute a “modification” of such ISOs (as that term is
defined in Section 424(h) of the Code) or would cause any adverse tax consequences for the holders of such ISOs. If the Administrator determines that such adjustments made with respect to ISOs would constitute a modification of such ISOs, it
may refrain from making such adjustments, unless the holder of an ISO specifically requests in writing that such adjustment be made and such writing indicates that the holder has full knowledge of the consequences of such “modification” on
his or her income tax treatment with respect to the ISO. 
  

	21.	ISSUANCES OF SECURITIES. 

 Except as expressly
provided herein, no issuance by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, shall affect, and no adjustment by reason thereof shall be made with respect to, the number or price of shares
subject to Stock Rights. Except as expressly provided herein, no adjustments shall be made for dividends paid in cash or in property (including without limitation, securities) of the Company prior to any issuance of Shares pursuant to a Stock Right.

  

	22.	FRACTIONAL SHARES. 

 No fractional shares shall be
issued under the Plan and the person exercising a Stock Right shall receive from the Company cash in lieu of such fractional shares equal to the Fair Market Value thereof. 
  

	23.	CONVERSION OF ISOs INTO NON-QUALIFIED OPTIONS; TERMINATION OF ISOs.- 

 The Administrator, at the written request of any Participant, may in its discretion take such actions as may be necessary to convert such Participant’s ISOs (or any portions thereof) that have not been exercised
on the date of conversion into Non-Qualified Options at any time prior to the expiration of such ISOs, regardless of whether the Participant is an employee of the Company or an Affiliate at the time of such conversion. Such actions may include, but
not be limited to, extending the exercise period or reducing the exercise price of the appropriate installments of such Options. At the time of such conversion, the Administrator (with the consent of the Participant) may impose such conditions on
the exercise of the resulting Non-Qualified Options as the Administrator in its discretion may determine, provided that such conditions shall not be inconsistent with this Plan. Nothing in the Plan shall be deemed to give any Participant the right
to have such Participant’s ISOs converted into Non-Qualified Options, 

  

 15 

 
and no such conversion shall occur until and unless the Administrator takes appropriate action. The Administrator, with the consent of the Participant, may
also terminate any portion of any ISO that has not been exercised at the time of such conversion. 
  

	24.	WITHHOLDING. 

 In the event that any federal, state,
or local income taxes, employment taxes, Federal Insurance Contributions Act withholdings or other amounts are required by applicable law or governmental regulation to be withheld from the Participant’s salary, wages or other remuneration in
connection with the exercise or acceptance of a Stock Right or in connection with a Disqualifying Disposition (as defined in Paragraph 25) or upon the lapsing of any right of repurchase, the Company may withhold from the Participant’s
compensation, if any, or may require that the Participant advance in cash to the Company, or to any Affiliate of the Company which employs or employed the Participant, the amount of such withholdings unless a different withholding arrangement,
including the use of shares of Common Stock or a promissory note, is authorized by the Administrator (and permitted by law). For purposes hereof, the fair market value of the shares withheld for purposes of payroll withholding shall be determined in
the manner provided in Paragraph 1 above, as of the most recent practicable date prior to the date of exercise. If the fair market value of the shares withheld is less than the amount of payroll withholdings required, the Participant may be required
to advance the difference in cash to the Company or the Affiliate employer. The Administrator in its discretion may condition the exercise of an Option for less than the then Fair Market Value on the Participant’s payment of such additional
withholding. 
  

	25.	NOTICE TO COMPANY OF DISQUALIFYING DISPOSITION. 

 Each Key Employee who receives an ISO must agree to notify the Company in writing immediately after the Key Employee makes a Disqualifying Disposition of any shares acquired pursuant to the exercise of an ISO. A “Disqualifying
Disposition” is any disposition (including any sale) of such shares before the later of (a) two years after the date the Key Employee was granted the ISO, or (b) one year after the date the Key Employee acquired Shares by exercising
the ISO. If the Key Employee has died before such stock is sold, these holding period requirements do not apply and no Disqualifying Disposition can occur thereafter. 
  

	26.	TERMINATION OF THE PLAN. 

 The Plan will terminate
on 10 years after adoption, the date which is ten (10) years from the earlier of the date of its adoption and the date of its approval by the shareholders of the Company. The Plan may be terminated at an earlier date by vote of the
shareholders of the Company; provided, however, that any such earlier termination shall not affect any Option Agreements or Stock Grant Agreements executed prior to the effective date of such termination. 
  

 16 

	27.	AMENDMENT OF THE PLAN AND AGREEMENTS. 

 The Plan may
be amended by the shareholders of the Company. The Plan may also be amended by the Administrator, including, without limitation, to the extent necessary to qualify any or all outstanding Stock Rights granted under the Plan or Stock Rights to be
granted under the Plan for favorable federal income tax treatment (including deferral of taxation upon exercise) as may be afforded incentive stock options under Section 422 of the Code, and to the extent necessary to qualify the shares
issuable upon exercise or acceptance of any outstanding Stock Rights granted, or Stock Rights to be granted, under the Plan for listing on any national securities exchange or quotation in any national automated quotation system of securities
dealers. Any amendment approved by the Administrator which the Administrator determines is of a scope that requires shareholder approval shall be subject to obtaining such shareholder approval. Any modification or amendment of the Plan shall not,
without the consent of a Participant, adversely affect his or her rights under a Stock Right previously granted to him or her. With the consent of the Participant affected, the Administrator may amend outstanding Option Agreements and Stock Grant
Agreements in a manner which may be adverse to the Participant but which is not inconsistent with the Plan. In the discretion of the Administrator, outstanding Option Agreements and Stock Grant Agreements may be amended by the Administrator in a
manner which is not adverse to the Participant. 
  

	28.	EMPLOYMENT OR OTHER RELATIONSHIP. 

 Nothing in this
Plan or any Option Agreement or Stock Grant Agreement shall be deemed to prevent the Company or an Affiliate from terminating the employment, consultancy or director status of a Participant, nor to prevent a Participant from terminating his or her
own employment, consultancy or director status or to give any Participant a right to be retained in employment or other service by the Company or any Affiliate for any period of time. 
  

	29.	GOVERNING LAW. 

 This Plan shall be construed and
enforced in accordance with the law of the State of Delaware. 
  

 17Second Amendment and Restated Stockholders Rights Agreement

 Exhibit 10.10 
 Execution Version 
 SECOND AMENDED AND RESTATED STOCKHOLDER RIGHTS AGREEMENT 
 This SECOND AMENDED AND RESTATED STOCKHOLDER RIGHTS AGREEMENT (this “Agreement”), dated as of September 4, 2007, is by and among
(a) Elixir Pharmaceuticals, Inc., a Delaware corporation (the “Company”), (b) the individuals and entities identified as Purchasers (the “Series A Purchasers”) in that certain Series A Convertible Preferred
Stock Purchase Agreement, dated as of December 29, 2000, by and among the Company and the Purchasers thereto (the “Series A Purchase Agreement”), which Series A Purchasers are listed on Schedule I below, (c) each of the
holders of Founders Stock named herein (the “Founders”), which Founders are listed on Schedule II below, (d) the individuals and entities identified as Purchasers (the “Series B Purchasers”) in that certain
Series B Convertible Preferred Stock Purchase Agreement, dated as of February 4, 2003, by and among the Company and the Purchasers thereto, as amended by those Amendments Nos. 1, 2 and 3, dated as of July 9,
2003, September 24, 2003 and February 2, 2004, respectively (as fully amended, the “Series B Purchase Agreement”), which Series B Purchasers are listed on Schedule III below, (e) Bristol-Myers Squibb Company,
a Delaware corporation (“BMS”), (f) the individuals and entities identified as Purchasers (the “Series C Purchasers”) in that certain Series C Convertible Preferred Stock Purchase Agreement, dated as of
June 19, 2006, by and among the Company and the Purchasers thereto (the “Series C Purchase Agreement”), which Series C Purchasers are listed on Schedule IV below, (g) the individuals and entities identified as Purchasers
(the “Series D Purchasers”) in that certain Series D Convertible Preferred Stock Purchase Agreement, dated as of September 4, 2007, by and among the Company and the Purchasers thereto (the “Purchase Agreement”),
which Series D Purchasers are listed on Schedule V below and (h) each other person or entity who or which becomes a party to this Agreement by executing an Instrument of Accession substantially on the terms and in the form of Exhibit A
hereto (an “Other Purchaser” and, collectively with the Series A Purchasers, the Series B Purchasers, the Series C Purchasers, the Series D Purchasers and BMS, the “Purchasers”). 
 WHEREAS, the Company is proposing to sell shares of its authorized and unissued Series D Convertible Preferred Stock, $0.001 par value per share, and
warrants to acquire shares or its authorized and unissued Common Stock (as defined below) pursuant to the terms of the Purchase Agreement (the transactions referred to therein are collectively referred to herein as the “Financing”); and

 WHEREAS, as a condition precedent to the Financing, the Company, the Purchasers (as defined in the Prior Agreement, as defined below), and
the purchasers under the Purchase Agreement desire to enter into this Agreement to amend and restate the Amended and Restated Stockholder Rights Agreement, dated as of June 19, 2006 (the “Prior Agreement”), among the Company and the
stockholders named therein in its entirety pursuant to the terms hereof; 
 NOW, THEREFORE, in consideration of the mutual promises and
covenants contained in this Agreement and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows: 
 1. Certain Definitions. As used in this Agreement, the following terms shall have the following respective meanings: 

 “Affiliate” shall include, with respect to a Purchaser which is a partnership or limited
liability company, its partners, members, former partners, former members or an entity managed by the same manager or managing partner or management company, or managed or owned by an entity controlling, controlled by, or under common control with,
such manager or managing partner or management company. 
 “BMS Agreement” shall mean that certain License Agreement by and
between BMS and the Company, dated as of April 25, 2005, as such agreement may be amended or restated. 
 “BMS Originally Issued
Common Shares “ shall means shares of Common Stock issued to BMS by the Company pursuant to Section 8.2.2(b) of the BMS Agreement (but not shares of Series B Preferred Stock, or Common Stock issued or issuable upon conversion
thereof, held by BMS, which shares are included in the Preferred Shares and Conversion Shares, respectively). 
 “Commission” shall mean the Securities and Exchange Commission, or any other federal agency at the time administering the Securities Act. 
 “Common Stock” shall mean the Common Stock, $0.001 par value per share, of the Company, as constituted as of the date of this Agreement. 
 “Conversion Shares” shall mean shares of Common Stock issued upon conversion of the Preferred Shares. 
 “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended, or any similar federal statute, and the rules and regulations
of the Commission thereunder, all as the same shall be in effect at the time. 
 “Founders Stock” shall mean the Common
Stock now owned or hereafter acquired by Leonard T. Guarente, Cynthia Kenyon, Cindy Bayley, Louis Kunkel and Annibale Puca. 
 “Preferred Shares” shall mean shares of Preferred Stock. 
 “Preferred Stock” shall mean the
Company’s Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock. 
 “Registration Expenses” shall mean the expenses so described in Section 8. 
 “Restricted
Stock” shall mean the Conversion Shares, any shares of Common Stock issued or issuable upon conversion of the warrants issued pursuant to the terms of the Series C Purchase Agreement or the Purchase Agreement (the “Warrant
Shares”) and the BMS Originally Issued Common Shares, excluding Conversion Shares, Warrant Shares and BMS Originally Issued Common Shares which have been (a) registered under the Securities Act pursuant to an effective registration
statement filed thereunder and disposed of in accordance with the registration statement covering them or (b) publicly sold pursuant to Rule 144 under the Securities Act. For the purposes of sections 5, 7, 8, 9, 11 and 12 hereof,
Restricted Stock shall also include Founders Stock. 
  

 2 

 “Securities Act” shall mean the Securities Act of 1933, as amended, or any similar
federal statute, and the rules and regulations of the Commission thereunder, all as the same shall be in effect at the time. 
 “Selling Expenses” shall mean the expenses so described in Section 8. 
 “Series A Preferred
Stock” shall mean the Series A Convertible Preferred Stock, $0.001 par value per share, together with the Series A-2 Convertible Preferred Stock, $0.001 par value per share, of the Company, each as constituted as of the date of
this Agreement. 
 “Series B Preferred Stock” shall mean the Series B Convertible Preferred Stock, $0.001 par
value per share, together with the Series B-1 Convertible Preferred Stock, $0.001 par value per share and the Series B-2 Convertible Preferred Stock, $0.001 par value per share, of the Company, each as constituted as of the date of this
Agreement. 
 “Series C Preferred Stock” shall mean the Series C Convertible Preferred Stock, $0.001 par value per
share, of the Company, as constituted as of the date of this Agreement. 
 “Series D Preferred Stock” shall mean the
Series D Convertible Preferred Stock, $0.001 par value per share, of the Company, as constituted as of the date of this Agreement. 
 2.
Restrictive Legend. Each certificate representing Preferred Shares, Conversion Shares, BMS Originally Issued Common Shares or Founders Stock shall, except as otherwise provided in this Section 2 or in Section 3, be stamped or
otherwise imprinted with a legend substantially in the following form: 
 “THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT
OF 1933 OR ANY STATE SECURITIES LAWS AND MAY NOT BE TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS IT HAS BEEN REGISTERED UNDER SUCH ACT AND ALL SUCH APPLICABLE LAWS OR AN EXEMPTION FROM REGISTRATION IS AVAILABLE.” 
 A certificate shall not bear such legend if in the opinion of counsel satisfactory to the Company (it being agreed that Goodwin Procter LLP shall be satisfactory) the
securities represented thereby may be publicly sold without registration under the Securities Act and any applicable state securities laws. 
 3. Notice of Proposed Transfer. Prior to any proposed transfer of any Preferred Shares, Conversion Shares, BMS Originally Issued Common Shares or Founders Stock (other than under the circumstances described in Sections 4, 5 or
6), the holder thereof shall give written notice to the Company of its intention to effect such transfer. Each such notice shall describe the manner of the proposed transfer and, if requested by the Company, shall be accompanied by an opinion of
counsel satisfactory to the Company (it being agreed that Goodwin Procter LLP shall be satisfactory) to the effect that the proposed transfer may be effected without registration under the Securities Act and any applicable state securities laws,

  

 3 

 
whereupon the holder of such stock shall be entitled to transfer such stock in accordance with the terms of its notice; provided, however, that
no such opinion of counsel shall be required for a transfer to one or more Affiliates of the transferor. Each certificate for Preferred Shares, Conversion Shares, BMS Originally Issued Common Shares or Founders Stock transferred as above provided
shall bear the legend set forth in Section 2, except that such certificate shall not bear such legend if (i) such transfer is in accordance with the provisions of Rule 144 (or any other rule permitting public sale without registration
under the Securities Act) or (ii) the opinion of counsel referred to above is to the further effect that the transferee and any subsequent transferee (other than an Affiliate of the Company) would be entitled to transfer such securities in a
public sale without registration under the Securities Act. The restrictions provided for in this Section 3 shall not apply to securities which are not required to bear the legend prescribed by Section 2 in accordance with the provisions of
that Section. 
 4. Required Registration. (a) At any time after the
earliest of (i) six (6) months after any registration statement covering the initial public offering of securities of the Company under the Securities Act shall have become effective, (ii) six (6) months after the Company shall
have become a reporting company under Section 12 of the Exchange Act, and (iii) the third (3rd) anniversary of the date of this Agreement,
the holders of Restricted Stock constituting at least 40% of the total shares of Restricted Stock then outstanding may request the Company to register under the Securities Act all or any portion of the shares of Restricted Stock held by such
requesting holder or holders for sale in the manner specified in such notice, provided that the shares of Restricted Stock for which registration has been requested shall constitute at least 20% of the total shares of Restricted Stock
originally issued if such holder or holders shall request the registration of less than all shares of Restricted Stock then held by such holder or holders (or any lesser percentage if the reasonably anticipated aggregate price to the public of such
public offering would exceed $5,000,000). For purposes of this Section 4 and Sections 5, 6, 13(a) and 13(d), the term “Restricted Stock” shall be deemed to include the number of shares of Restricted Stock which would be issuable
to a holder of Preferred Shares upon conversion of all Preferred Shares held by such holder at such time, provided, however, that the only securities which the Company shall be required to register pursuant hereto shall be shares of
Common Stock, and provided, further, however, that, in any underwritten public offering contemplated by this Section 4 or Sections 5 and 6, the holders of Preferred Shares shall be entitled to sell such Preferred
Shares to the underwriters for conversion and sale of the shares of Common Stock issued upon conversion thereof. Notwithstanding anything to the contrary contained herein, no request may be made under this Section 4 within one hundred eighty
(180) days after the effective date of a registration statement filed by the Company covering a firm commitment underwritten public offering in which the holders of Restricted Stock shall have been entitled to join pursuant to Sections 5
or 6 and in which there shall have been effectively registered all shares of Restricted Stock as to which registration shall have been requested. 
 (b) Following receipt of any notice under this Section 4, the Company shall immediately notify all holders of Restricted Stock from whom notice has not been received and shall use its best efforts to register
under the Securities Act, for public sale in accordance with the method of disposition specified in such notice from requesting holders, the number of shares of Restricted Stock specified in such notice (and in all notices received by the Company
from other holders within thirty (30) days after the giving of such notice by the Company). If such method of disposition shall be an underwritten public offering, the holders of a majority of the 

  

 4 

 
shares of Restricted Stock to be sold in such offering may designate the managing underwriter of such offering, subject to the approval of the Company, which
approval shall not be unreasonably withheld or delayed. The Company shall be obligated to register Restricted Stock pursuant to this Section 4 on two occasions only, provided, however, that such obligation shall be deemed
satisfied only when a registration statement covering all shares of Restricted Stock specified in notices received as aforesaid, for sale in accordance with the method of disposition specified by the requesting holders, shall have become effective.

 (c) The Company shall be entitled to include in any registration statement referred to in this Section 4, for sale in accordance with
the method of disposition specified by the requesting holders, shares of Common Stock to be sold by the Company for its own account, except as and to the extent that, in the opinion of the managing underwriter (if such method of disposition shall be
an underwritten public offering), such inclusion would adversely affect the marketing of the Restricted Stock to be sold. Except for registration statements on Form S-4, S-8 or any successor thereto, the Company will not file with the
Commission any other registration statement with respect to its Common Stock, whether for its own account or that of other stockholders, from the date of receipt of a notice from requesting holders pursuant to this Section 4 until the
completion of the period of distribution of the registration contemplated thereby. 
 5. Incidental Registration. If the Company at
any time (other than pursuant to Section 4 or Section 6) proposes to register any of its securities under the Securities Act for sale to the public, whether for its own account or for the account of other security holders or both (except
with respect to registration statements on Forms S-4, S-8 or another form not available for registering the Restricted Stock for sale to the public), each such time it will give written notice to all holders of outstanding Restricted Stock of
its intention so to do. Upon the written request of any such holder, received by the Company within thirty (30) days after the giving of any such notice by the Company, to register any of its Restricted Stock, the Company will use its best
efforts to cause the Restricted Stock as to which registration shall have been so requested to be included in the securities to be covered by the registration statement proposed to be filed by the Company, all to the extent requisite to permit the
sale or other disposition by the holder of such Restricted Stock so registered. In the event that any registration pursuant to this Section 5 shall be, in whole or in part, an underwritten public offering of Common Stock, the number of shares
of Restricted Stock to be included in such an underwriting may be reduced pro rata among the requesting holders based upon the number of shares of Restricted Stock owned by such holders if and to the extent that the managing underwriter shall be of
the opinion that such inclusion would adversely affect the marketing of the securities to be sold by the Company therein, provided, however, that such number of shares of Restricted Stock shall not be reduced if any shares are to be
included in such underwriting for the account of any person other than the Company or requesting holders of Restricted Stock. Notwithstanding the foregoing provisions, the Company may withdraw any registration statement referred to in this
Section 5 without thereby incurring any liability to the holders of Restricted Stock, and further, the Company shall not be required, pursuant to this Section 5, to include any Restricted Stock in a Registration Statement if such
Restricted Stock can then be sold pursuant to Rule 144(k). 
 6. Registration on Form S-3. If at any time (i) a holder or
holders of Preferred Shares or Restricted Stock request that the Company file a registration statement on Form S-3 or 

  

 5 

 
any successor thereto for a public offering of all or any portion of the shares of Restricted Stock held by such requesting holder or holders, the reasonably
anticipated aggregate price to the public of which would exceed $1,000,000, and (ii) the Company is a registrant entitled to use Form S-3 or any successor thereto to register such shares, then the Company shall use its best efforts to
register under the Securities Act on Form S-3 or any successor thereto, for public sale in accordance with the method of disposition specified in such notice, the number of shares of Restricted Stock specified in such notice. Whenever the
Company is required by this Section 6 to use its best efforts to effect the registration of Restricted Stock, each of the procedures and requirements of Section 4 (including but not limited to the requirement that the Company notify all
holders of Restricted Stock from whom notice has not been received and provide them with the opportunity to participate in the offering) shall apply to such registration, provided, however, that there shall be no limitation on the
number of registrations on Form S-3 which may be requested and obtained under this Section 6, and provided, further, however, that the requirements contained in the first sentence of Section 4(a) shall not apply
to any registration on Form S-3 which may be requested and obtained under this Section 6. 
 7. Registration Procedures. If
and whenever the Company is required by the provisions of Sections 4, 5 or 6 to use its best efforts to effect the registration of any shares of Restricted Stock under the Securities Act, the Company will, as expeditiously as is reasonable:

 (a) prepare and file with the Commission a registration statement (which, in the case of an underwritten public offering pursuant to
Section 4, shall be on Form S-1 or other form of general applicability satisfactory to the managing underwriter selected as therein provided) with respect to such securities and use its best efforts to cause such registration statement to
become and remain effective for the period of the distribution contemplated thereby (determined as hereinafter provided); 
 (b) prepare and
file with the Commission such amendments and supplements to such registration statement and the prospectus used in connection therewith as may be necessary to keep such registration statement effective for the period specified in paragraph (a)
above and comply with the provisions of the Securities Act with respect to the disposition of all Restricted Stock covered by such registration statement in accordance with the sellers’ intended method of disposition set forth in such
registration statement for such period; 
 (c) furnish to each seller of Restricted Stock and to each underwriter such number of copies of
the registration statement and the prospectus included therein (including each preliminary prospectus) as such persons reasonably may request in order to facilitate the public sale or other disposition of the Restricted Stock covered by such
registration statement; 
 (d) use its best efforts to register or qualify the Restricted Stock covered by such registration statement under
the securities or “blue sky” laws of such jurisdictions as the sellers of Restricted Stock or, in the case of an underwritten public offering, the managing underwriter reasonably shall request, provided, however, that the
Company shall not for any such purpose be required to qualify generally to transact business as a foreign corporation in any jurisdiction where it is not so qualified or to consent to general service of process in any such jurisdiction; 

 

 6 

 (e) use its best efforts to list the Restricted Stock covered by such registration statement with any
securities exchange on which the Common Stock of the Company is then listed; 
 (f) immediately notify each seller of Restricted Stock and
each underwriter under such registration statement, at any time when a prospectus relating thereto is required to be delivered under the Securities Act, of the happening of any event of which the Company has knowledge as a result of which the
prospectus contained in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in
light of the circumstances then existing; 
 (g) if the offering is underwritten and at the request of any seller of Restricted Stock, use
its best efforts to furnish on the date that Restricted Stock is delivered to the underwriters for sale pursuant to such registration: (i) an opinion dated such date of counsel representing the Company for the purposes of such registration,
addressed to the underwriters and to such seller, stating that such registration statement has become effective under the Securities Act and that (A) to the knowledge of such counsel, no stop order suspending the effectiveness thereof has been
issued and no proceedings for that purpose have been instituted or are pending or contemplated under the Securities Act, (B) the registration statement, the related prospectus and each amendment or supplement thereof comply as to form in all
material respects with the requirements of the Securities Act (except that such counsel need not express any opinion as to financial statements contained therein) and (C) to such other effects as reasonably may be requested by counsel for the
underwriters or by such seller or its counsel and (ii) a letter dated such date from the independent public accountants retained by the Company, addressed to the underwriters and to such seller, stating that they are independent public
accountants within the meaning of the Securities Act and that, in the opinion of such accountants, the financial statements of the Company included in the registration statement or the prospectus, or any amendment or supplement thereof, comply as to
form in all material respects with the applicable accounting requirements of the Securities Act, and such letter shall additionally cover such other financial matters (including information as to the period ending no more than five (5) business
days prior to the date of such letter) with respect to such registration as such underwriters reasonably may request; and 
 (h) make
available for inspection by each seller of Restricted Stock, any underwriter participating in any distribution pursuant to such registration statement, and any attorney, accountant or other agent retained by such seller or underwriter, all financial
and other records, pertinent corporate documents and properties of the Company, and cause the Company’s officers, directors and employees to supply all information reasonably requested by any such seller, underwriter, attorney, accountant or
agent in connection with such registration statement. 
 For purposes of Section 7(a) and 7(b) and of Section 4(c), the period of
distribution of Restricted Stock in a firm commitment underwritten public offering shall be deemed to extend until each underwriter has completed the distribution of all securities purchased by it, and the period of distribution of Restricted Stock
in any other registration shall be deemed to extend until the earlier of the sale of all Restricted Stock covered thereby and one hundred twenty (120) days after the effective date thereof. 
  

 7 

 In connection with each registration hereunder, the sellers of Restricted Stock will furnish to the
Company in writing such information with respect to themselves and the proposed distribution by them as reasonably shall be necessary in order to assure compliance with federal and applicable state securities laws. 
 In connection with each registration pursuant to Sections 4, 5 or 6 covering an underwritten public offering, the Company and each seller agree to
enter into a written agreement with the managing underwriter selected in the manner herein provided in such form and containing such provisions as are customary in the securities business for such an arrangement between such underwriter and
companies of the Company’s size and investment stature. 
 8. Expenses. All expenses incurred by the Company in complying with
Sections 4, 5 and 6, including, without limitation, all registration and filing fees, printing expenses, fees and disbursements of counsel and independent public accountants for the Company, fees and expenses (including counsel fees) incurred
in connection with complying with state securities or “blue sky” laws, fees of the National Association of Securities Dealers, Inc., transfer taxes, fees of transfer agents and registrars, costs of insurance and fees and disbursements of
one counsel for the sellers of Restricted Stock, but excluding any Selling Expenses, are called “Registration Expenses.” All underwriting discounts and selling commissions applicable to the sale of Restricted Stock are called “Selling
Expenses.” 
 The Company will pay all Registration Expenses in connection with each registration statement under Sections 4, 5 or
6. All Selling Expenses in connection with each registration statement under Sections 4, 5 or 6 shall be borne by the participating sellers in proportion to the number of shares sold by each, or by such participating sellers other than the
Company (except to the extent the Company shall be a seller) as they may agree. 
 9. Indemnification and Contribution. (a) In
the event of a registration of any of the Restricted Stock under the Securities Act pursuant to Sections 4, 5 or 6, the Company will indemnify and hold harmless each seller of such Restricted Stock thereunder, each underwriter of such
Restricted Stock thereunder and each other person, if any, who controls such seller or underwriter within the meaning of the Securities Act, against any losses, claims, damages or liabilities, joint or several, to which such seller, underwriter or
controlling person may become subject under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any untrue statement or alleged untrue statement of
any material fact contained in any registration statement under which such Restricted Stock was registered under the Securities Act pursuant to Sections 4, 5 or 6, any preliminary, free writing or final prospectus contained therein, or any
amendment or supplement thereof, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse each
such seller thereunder, each such underwriter and each such controlling person for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action,
provided, however, that the Company will not be liable in any such case if and to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement or omission or
alleged omission so made in conformity with information furnished by any such seller, any such underwriter or any such controlling person in writing specifically for use in such registration statement or prospectus. 
  

 8 

 (b) In the event of a registration of any of the Restricted Stock under the Securities Act pursuant to
Sections 4, 5 or 6, each seller of such Restricted Stock thereunder, severally and not jointly, will indemnify and hold harmless the Company, each person, if any, who controls the Company within the meaning of the Securities Act, each officer
of the Company who signs the registration statement, each director of the Company, each underwriter and each person who controls any underwriter within the meaning of the Securities Act, against all losses, claims, damages or liabilities, joint or
several, to which the Company or such officer, director, underwriter or controlling person may become subject under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of
or are based upon any untrue statement or alleged untrue statement of any material fact contained in the registration statement under which such Restricted Stock was registered under the Securities Act pursuant to Sections 4, 5 or 6, any
preliminary, free writing or final prospectus contained therein, or any amendment or supplement thereof, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary
to make the statements therein not misleading, and will reimburse the Company and each such officer, director, underwriter and controlling person for any legal or other expenses reasonably incurred by them in connection with investigating or
defending any such loss, claim, damage, liability or action, provided, however, that such seller will be liable hereunder in any such case only if and only to the extent that any such loss, claim, damage or liability arises out of or
is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with information pertaining to such seller, as such, furnished in writing to the Company by such seller
specifically for use in such registration statement or prospectus, and provided, further, however, that the liability of each seller hereunder shall be limited to the proportion of any such loss, claim, damage, liability or
expense which is equal to the proportion that the public offering price of the shares sold by such seller under such registration statement bears to the total public offering price of all securities sold thereunder, but not in any event to exceed
the net proceeds received by such seller from the sale of Restricted Stock covered by such registration statement. 
 (c) Promptly after
receipt by an indemnified party hereunder of notice of the commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party hereunder, notify the indemnifying party in writing
thereof, but the omission so to notify the indemnifying party shall not relieve it from any liability which it may have to such indemnified party other than under this Section 9 and shall only relieve it from any liability which it may have to
such indemnified party under this Section 9 if and to the extent the indemnifying party is prejudiced by such omission. In case any such action shall be brought against any indemnified party and it shall notify the indemnifying party of the
commencement thereof, the indemnifying party shall be entitled to participate in and, to the extent it shall wish, to assume and undertake the defense thereof with counsel satisfactory to such indemnified party, and, after notice from the
indemnifying party to such indemnified party of its election so to assume and undertake the defense thereof, the indemnifying party shall not be liable to such indemnified party under this Section 9 for any legal expenses subsequently incurred
by such indemnified party in connection with the defense thereof other than reasonable costs of investigation and of liaison with counsel so selected, provided, however, that, if the 

  

 9 

 
defendants in any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that
there may be reasonable defenses available to it which are different from or additional to those available to the indemnifying party or if the interests of the indemnified party reasonably may be deemed to conflict with the interests of the
indemnifying party, the indemnified party shall have the right to select a separate counsel and to assume such legal defenses and otherwise to participate in the defense of such action, with the reasonable expenses and fees of such separate counsel
and other expenses related to such participation to be reimbursed by the indemnifying party as incurred; provided further, that in no event shall the indemnifying party be required to pay the expenses of more than one law firm as counsel for
the indemnified party. 
 (d) In order to provide for just and equitable contribution to joint liability under the Securities Act in any case
in which either (i) any holder of Restricted Stock exercising rights under this Agreement, or any controlling person of any such holder, makes a claim for indemnification pursuant to this Section 9 but it is judicially determined (by the
entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case notwithstanding the fact that this
Section 9 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any such selling holder or any such controlling person in circumstances for which indemnification is provided
under this Section 9, then, and in each such case, the Company and such holder will contribute to the aggregate losses, claims, damages or liabilities to which they may be subject (after contribution from others) in such proportion so that such
holder is responsible for the portion represented by the percentage that the public offering price of its Restricted Stock offered by the registration statement bears to the public offering price of all securities offered by such registration
statement, and the Company is responsible for the remaining portion; provided, however, that, in any such case: (A) no such holder will be required to contribute any amount in excess of the public offering price of all such
Restricted Stock offered by it pursuant to such registration statement; and (B) no person or entity guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from
any person or entity who was not guilty of such fraudulent misrepresentation. Any party entitled to contribution will, promptly after receipt of notice of commencement of any action, suit or proceeding against such party in respect of which a claim
for contribution may be made against another party or parties under this Section, notify such party or parties from whom contribution may be sought, but the omission so to notify such party or parties from whom contribution may be sought shall not
relieve such party from any other obligation it or they may have thereunder or otherwise under this Section. No party shall be liable for contribution with respect to any action, suit, proceeding or claim settled without its prior written consent,
which consent shall not be unreasonably withheld. 
 10. Changes in Common Stock or Preferred Stock. If, and as often as, there is any
change in the Common Stock or the Preferred Stock by way of a stock split, stock dividend, combination or reclassification, or through a merger, consolidation, reorganization or recapitalization, or by any other means, appropriate adjustment shall
be made in the provisions hereof so that the rights and privileges granted hereby shall continue with respect to the Common Stock or the Preferred Stock as so changed. 
  

 10 

 11. Rule 144 Reporting. With a view to making available the benefits of certain rules and
regulations of the Commission which may at any time permit the sale of the Restricted Stock to the public without registration, at all times after ninety (90) days after any registration statement covering a public offering of securities of the
Company under the Securities Act shall have become effective, the Company agrees to: 
 (a) make and keep public information available, as
those terms are understood and defined in Rule 144 under the Securities Act; 
 (b) use its best efforts to file with the Commission in
a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act; and 
 (c) furnish to
each holder of Restricted Stock forthwith upon request a written statement by the Company as to its compliance with the reporting requirements of such Rule 144 and of the Securities Act and the Exchange Act, a copy of the most recent annual or
quarterly report of the Company, and such other reports and documents so filed by the Company as such holder may reasonably request in availing itself of any rule or regulation of the Commission allowing such holder to sell any Restricted Stock
without registration. 
 12. Covenants of the Company. The Company covenants and agrees with each of the Purchasers that: 

(a) Financial Statements, Reports, Etc. The Company shall furnish to each Purchaser holding 750,000 Preferred Shares and/or Conversion Shares:

 1. within ninety (90) days after the end of each fiscal year of the Company a consolidated balance sheet of the Company and its
subsidiaries, if any, as of the end of such fiscal year and the related consolidated statements of income, stockholders’ equity and cash flows for the fiscal year then ended, prepared in accordance with generally accepted accounting principles
and certified by a firm of independent public accountants of recognized national standing selected by the board of directors of the Company (the “Board of Directors”); 
 2. within thirty (30) days after the end of each month in each fiscal year (other than the last month in each fiscal year) a consolidated balance
sheet of the Company and its subsidiaries, if any, and the related consolidated statements of income, stockholders’ equity and cash flows, unaudited but prepared in accordance with generally accepted accounting principles and certified by the
principal financial officer of the Company, such consolidated balance sheet to be as of the end of such month and such consolidated statements of income, stockholders’ equity and cash flows to be for such month and for the period from the
beginning of the fiscal year to the end of such month, in each case with comparative statements for the prior fiscal year; 
 3. within
forty-five (45) days after the end of each fiscal quarter a consolidated balance sheet of the Company and its subsidiaries, if any, and the related consolidated statements of income, stockholders’ equity and cash flows, unaudited but
prepared in accordance with generally accepted accounting principles and certified by the principal financial officer of the Company, such consolidated balance sheet to be as of the end of such fiscal quarter and such consolidated statements of
income, stockholders’ equity and cash flows to be for such fiscal quarter and for the period from the beginning of the fiscal year to the end of such fiscal quarter, in each case with comparative statements for the prior fiscal year;

  

 11 

 4. at the time of delivery of each annual financial statement pursuant to Section 12(a)(1),
(i) a certificate executed by the principal financial officer of the Company stating that such officer has caused this Agreement and the Preferred Stock to be reviewed and has no knowledge of any default by the Company in the performance or
observance of any of the provisions of this Agreement or the Preferred Stock or, if such officer has such knowledge, specifying such default and the nature thereof and (ii) a capitalization table reflecting the fully-diluted ownership of the
capital stock of the Company as of the last day of the fiscal year presented in such financial statements; 
 5. at the time of delivery of
each quarterly statement pursuant to Section 12(a)(3), (i) a management narrative report explaining all significant variances from forecasts and all significant current developments in staffing, marketing, sales and operations and
(ii) a capitalization table reflecting the fully-diluted ownership of the capital stock of the Company as of the last day of the fiscal quarter presented in such quarterly statement; 
 6. promptly following each future equity financing, hypothetical liquidation waterfall illustrations based on one times (1x), one-half times
(1.5x) and two times (2x) the post-money valuation of the Company as of such equity financing and other facts and reasonable estimates as of the last day of the quarter prior to the quarter in which such equity financing occurs;

 7. no later than thirty (30) days prior to the start of each fiscal year, consolidated capital and operating expense budgets, cash
flow projections and income and loss projections for the Company and its subsidiaries in respect of such fiscal year, all itemized in reasonable detail and prepared on a monthly basis, and, promptly after preparation, any revisions to any of the
foregoing; 
 8. promptly following receipt by the Company, each audit response letter, accountant’s management letter and other written
report submitted to the Company by its independent public accountants in connection with an annual or interim audit of the books of the Company or any of its subsidiaries; 
 9. promptly after the commencement thereof, notice of: (i) all actions, suits, claims, proceedings, investigations and inquiries of the type
described in Section 3.7 of the Purchase Agreement, if any; (ii) any material breach of the covenants set forth in Section 12 hereof; (iii) any event which causes any representation and warranty in the Series A Purchase
Agreement, the Series B Purchase Agreement, the Series C Purchase Agreement or the Purchase Agreement to become materially untrue as of the date such representation or warranty was made; (iv) any material labor disputes in which the Company is
involved; and (v) any other material adverse change to the Company’s business, prospects, financial condition, operations, property or affairs; 
  

 12 

 10. promptly upon sending, making available or filing the same, all press releases, reports and financial
statements that the Company sends or makes available to its stockholders or directors or files with the Commission; and 
 11. promptly, from
time to time, such other information regarding the business, prospects, financial condition, operations, property or affairs of the Company and its subsidiaries as such Purchaser reasonably may request. 
 (b) Right of Participation. The Company shall, prior to any proposed issuance by the Company of any of its securities (other than the Subsequent
Closing Shares and Subsequent Closing Warrants, each as defined in the Purchase Agreement, and debt securities with no equity feature), offer to each Purchaser by written notice the right, for a period of thirty (30) days, to purchase for cash
at an amount equal to the price or other consideration for which such securities are to be issued, a number of such securities so that, after giving effect to such issuance (and the conversion, exercise and exchange into or for (whether directly or
indirectly) shares of Common Stock of all such securities that are so convertible, exercisable or exchangeable), such Purchaser will continue to maintain its same proportionate equity ownership in the Company as of the date of such notice (treating
each Purchaser, for the purpose of such computation, as the holder of the number of shares of Common Stock which would be issuable to such Purchaser upon conversion, exercise and exchange of all securities (including but not limited to the Preferred
Shares) held by such Purchaser on the date such offer is made, that are convertible, exercisable or exchangeable into or for (whether directly or indirectly) shares of Common Stock and assuming the like conversion, exercise and exchange of all such
other securities held by all other securityholders); provided, however, that the participation rights of the Purchasers pursuant to this Section 12(b) shall not apply to securities issued (A) upon conversion of any of the
Preferred Shares, (B) as a stock dividend or upon any subdivision of shares of Common Stock, provided, however, that the securities issued pursuant to such stock dividend or subdivision are limited to additional shares of Common
Stock, (C) pursuant to subscriptions, warrants, options, convertible securities, or other rights which are listed in the Corporation Disclosure Schedules to the Purchase Agreement as being outstanding on the date of this Agreement,
(D) solely in consideration for the acquisition (whether by merger or otherwise) by the Company or any of its subsidiaries of all or substantially all of the stock or assets of any other entity, (E) pursuant to a firm commitment public
offering, (F) pursuant to the exercise of options to purchase Common Stock granted to directors, officers, employees or consultants of the Company in connection with their service to the Company, pursuant to stock option plans approved by the
Board of Directors, not to exceed in the aggregate the Option Basket (as such term is defined below) (appropriately adjusted to reflect stock splits, stock dividends, combinations of shares and the like with respect to the Common Stock) (the shares
exempted by this clause (G) being hereinafter referred to as the “Reserved Employee Shares”), (H) in connection with any equipment lease financing, licensing, collaboration, or other joint venture transaction approved by a
majority of the Board of Directors, which majority must include each of the Purchaser Nominees (as such term is defined in the Fourth Amended and Restated Voting Agreement dated as of the date hereof (the “Voting Agreement”) by and
among the Company and the stockholder parties thereto), (I) shares of capital stock of the Company issued and sold to a collaborative partner of the Company in a private placement closing simultaneously with the closing of the Company’s
initial public offering, provided that such issuance and sale is approved by a majority of the Board of Directors, which majority must include each of the Purchaser Nominees, (J) pursuant to the 

  

 13 

 
Purchase Agreement or shares issuable upon conversion or exercise of securities issued pursuant to the Purchase Agreement, (K) pursuant to the Compton
Agency Agreement (as defined in the Purchase Agreement) or (L) upon exercise of any right that was not itself in violation of the terms of this Section 12(b). The Company’s written notice to the Purchasers shall describe the
securities proposed to be issued by the Company and specify the number, price and payment terms. Each Purchaser may accept the Company’s offer as to the full number of securities offered to it or any lesser number, by written notice thereof
given by it to the Company prior to the expiration of the aforesaid thirty (30) day period, in which event the Company shall promptly sell and such Purchaser shall buy, upon the terms specified, the number of securities agreed to be purchased
by such Purchaser. The Company shall be free at any time prior to ninety (90) days after the date of its notice of offer to the Purchasers, to offer and sell to any third party or parties the remainder of such securities proposed to be issued
by the Company (including but not limited to the securities not agreed by the Purchasers to be purchased by them), at a price and on payment terms no less favorable to the Company than those specified in such notice of offer to the Purchasers.
However, if such third party sale or sales are not consummated within such ninety (90) day period, the Company shall not sell such securities as shall not have been purchased within such period without again complying with this
Section 12(b). The Purchasers shall have a right of over-subscription such that if any Purchaser fails to accept the Company’s offer as to the full number of securities offered to such Purchaser pursuant to this Section 12(b), the
other Purchasers shall, among them, have the right to purchase up to the balance of the offered securities not so purchased. Such right of over-subscription may be exercised by a Purchaser by accepting the Company’s offer as to more than the
full amount of securities offered to such Purchaser. If, as a result thereof, such over-subscriptions exceed the total number of securities available in respect of such over-subscription privilege, the oversubscribing Purchasers shall be cut back
with respect to their over-subscriptions on a pro rata basis in accordance with the full number of securities offered to each of them by the Company or as they may otherwise agree among themselves. 
 For the purposes of Section 12(b), the term “Option Basket” shall mean that number of shares equal to 23,523,824 (equitably adjusted to
reflect stock splits, stock dividends, combinations of shares and the like); provided, that such amount of shares may be increased upon approval by a majority of the Board of Directors (which majority shall include the Purchaser Nominees) of
an increase in the amount of shares covered by an existing or newly-approved equity incentive plan. 
 (c) Reserve for Conversion
Shares. The Company shall at all times reserve and keep available out of its authorized but unissued shares of Common Stock, for the purpose of effecting the conversion of the Preferred Shares and otherwise complying with the terms of this
Agreement, such number of its duly authorized shares of Common Stock as shall be sufficient to effect the conversion of the Preferred Shares from time to time outstanding or otherwise to comply with the terms of this Agreement. If at any time the
number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of the Preferred Shares or otherwise to comply with the terms of this Agreement, the Company will forthwith take such corporate action as may
be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes. The Company will obtain any authorization, consent, approval or other action by or make any filing with
any court or administrative body that may be required under applicable state securities laws in connection with the issuance of shares of Common Stock upon conversion of the Preferred Shares. 
  

 14 

 (d) Corporate Existence. The Company shall preserve, protect and maintain and, except as otherwise
permitted by Section 12(o) cause each of its subsidiaries (if any) to preserve, protect and maintain, their respective corporate existence, rights, franchises and privileges and all properties necessary or useful to the proper conduct of its
business. 
 (e) Properties, Business, Insurance. The Company shall maintain and cause each of its subsidiaries (if any) to maintain
as to their respective properties and business, with financially sound and reputable insurers, insurance against such casualties and contingencies and of such types and in such amounts as is customary for companies similarly situated, which
insurance shall be deemed by the Company to be sufficient. The Company shall obtain within ninety (90) days of the date hereof and shall thereafter maintain in effect a directors and officers insurance policy, such policy with terms and in an
amount consistent with industry standards for similarly situated companies which shall be mutually agreed to by the Company and the Initial Purchasers (as defined in the Purchase Agreement). The Company shall not cause or permit any assignment or
change in beneficiary and shall not borrow against any such policy. If requested by Purchasers holding at least a majority of the outstanding Preferred Shares, the Company will add one designee of such Purchasers as a notice party for each such
policy and shall request that the issuer of each policy provide such designee with ten (10) days’ notice before such policy is terminated (for failure to pay premiums or otherwise) or assigned or before any change is made in the
beneficiary thereof. 
 (f) Inspection, Consultation and Advice. The Company shall permit and cause each of its subsidiaries (if any)
to permit each Purchaser holding 750,000 Preferred Shares and/or Conversion Shares and such persons as it may designate, at such Purchaser’s expense, to visit and inspect any of the properties of the Company and its subsidiaries, examine their
books and take copies and extracts therefrom, discuss the affairs, finances and accounts of the Company and its subsidiaries with their officers, employees and public accountants (and the Company hereby authorizes said accountants to discuss with
such Purchaser and such designees such affairs, finances and accounts), and consult with and advise the management of the Company and its subsidiaries as to their affairs, finances and accounts, all during normal business hours and upon reasonable
notice. 
 (g) Restrictive Agreements Prohibited. Neither the Company nor any of its subsidiaries shall become a party to any
agreement which by its terms restricts the Company’s performance of any of the Purchase Agreement, the Ancillary Agreements (as defined in the Purchase Agreement) or the Restated Certificate (as defined in the Purchase Agreement). 

(h) Transactions with Affiliates. Except for transactions contemplated by this Agreement or as otherwise approved by the Board of Directors,
neither the Company nor any of its subsidiaries shall enter into any transaction with any director, officer, employee or holder of more than 5% of the outstanding capital stock of any class or series of capital stock of the Company or any of its
subsidiaries, member of the family of any such person, or any corporation, partnership, trust or other entity in which any such person, or member of the family of any such person, is a director, officer, trustee, partner or holder of more than 5% of
the outstanding capital stock thereof, except for transactions on customary terms related to such person’s employment. 
  

 15 

 (i) Expenses of Directors. The Company shall promptly reimburse in full, each director of the
Company who is not an employee of the Company and who was elected as a director solely or in part by the holders of Series B Preferred Stock or Series D Preferred Stock for all of his reasonable out-of-pocket expenses incurred in attending each
meeting of the Board of Directors or any Committee thereof. 
 (j) Board of Directors Meetings. The Company shall use its best efforts
to ensure that meetings of the Board of Directors are held at least four (4) times each year and at least once each quarter. Pursuant to those certain letter agreements, by and between the Company and each of Tredegar Investments and the
Trustees of Boston University, the Company shall, pursuant to the terms and conditions of such letter agreements, permit each such person to have one (1) representative attend each meeting of the Board of Directors and each meeting of any
Committee thereof and to participate in all discussions during each such meeting. The Company shall send to each such Purchaser and designee the notice of the time and place of such meeting in the same manner and at the same time as it shall send
such notice to its directors or committee members, as the case may be. The Company shall also provide to each such Purchaser and designee copies of all notices, reports, minutes and consents at the time and in the manner as they are provided to the
Board of Directors or Committee, except for information reasonably designated as proprietary information by the Board of Directors. 
 (k)
By-laws. The Company shall at all times cause its By-laws to provide that, (a) unless otherwise required by the laws of the State of Delaware, (i) any two (2) directors or (ii) any holder or holders of at least twenty-five
percent (25%) of the outstanding shares of Preferred Stock, shall have the right to call a meeting of the Board of Directors or stockholders and (b) the number of directors fixed in accordance therewith shall in no event conflict with any
of the terms or provisions of the Third Amended and Restated Certificate of Incorporation. The Company shall at all times maintain provisions in its By-laws and/or Third Amended and Restated Certificate of Incorporation indemnifying all directors
against liability and absolving all directors from liability to the Company and its stockholders to the maximum extent permitted under the laws of the State of Delaware. 
 (l) Performance of Contracts. The Company shall not materially amend, modify, terminate, waive or otherwise alter, in whole or in part, any of the Employee NDAs (as defined in the Purchase Agreement) or the
non-competition agreements without the approval of the Board of Directors. 
 (m) Vesting of Reserved Employee Shares. The Company
shall not grant to any of its employees options to purchase Reserved Employee Shares which will become exercisable at a rate in excess of 25% per annum from the date of such grant without the unanimous written consent of the Purchaser Nominees.

 (n) Employee Nondisclosure and Development Agreements. The Company shall use its best efforts to obtain, and shall cause its
subsidiaries (if any) to use their best efforts to obtain, an Employee NDA in substantially the form of Exhibit I-1 or Exhibit I-2 to the Purchase 

  

 16 

 
Agreement from all future officers, key employees and other employees who will have access to confidential information of the Company or any of its
subsidiaries, upon their employment by the Company or any of its subsidiaries. 
 (o) Activities of Subsidiaries. The Company will not
organize or acquire any entity that is a subsidiary unless such subsidiary is wholly-owned (directly or indirectly) by the Company. The Company shall not permit any subsidiary to consolidate or merge into or with or sell or transfer all or
substantially all its assets, except that any subsidiary may (i) consolidate or merge into or with or sell or transfer assets to any other subsidiary, or (ii) merge into or sell or transfer assets to the Company. The Company shall not sell
or otherwise transfer any shares of capital stock of any subsidiary, except to the Company or another subsidiary, or permit any subsidiary to issue, sell or otherwise transfer any shares of its capital stock or the capital stock of any subsidiary,
except to the Company or another subsidiary. The Company shall not permit any subsidiary to purchase or set aside any sums for the purchase of, or pay any dividend or make any distribution on, any shares of its stock, except for dividends or other
distributions payable to the Company or another subsidiary. 
 (p) Compliance with Laws. The Company shall comply, and cause each
subsidiary to comply, with all applicable laws, rules, regulations and orders, noncompliance with which could materially adversely affect its business or condition, financial or otherwise. 
 (q) Keeping of Records and Books of Account. The Company shall keep, and cause each subsidiary to keep, adequate records and books of account, in
which complete entries will be made in accordance with generally accepted accounting principles consistently applied, reflecting all financial transactions of the Company and such subsidiary, and in which, for each fiscal year, all proper reserves
for depreciation, depletion, obsolescence, amortization, taxes, bad debts and other purposes in connection with its business shall be made. 
 (r) Change in Nature of Business; Transfer of Assets. The Company shall not make, or permit any subsidiary to make, any material change in the nature of its business as set forth in the Business Plan (as defined in the Purchase
Agreement), or make a material transfer of its assets, without the written consent of each of the Purchaser Nominees. 
 (s) U.S. Real
Property Interest Statement. The Company shall provide prompt written notice to each Purchaser following any “determination date” (as defined in Treasury Regulation Section 1.897-2(c)(i)) on which the Company becomes a United
States real property holding corporation. In addition, upon a written request by any Purchaser, the Company shall provide such Purchaser with a written statement informing the Purchaser whether such Purchaser’s interest in the Company
constitutes a U.S. real property interest. The Company’s determination shall comply with the requirements of Treasury Regulation Section 1.897-2(h)(1) or any successor regulation, and the Company shall provide timely notice to the Internal
Revenue Service, in accordance with and to the extent required by Treasury Regulation Section 1.897-2(h)(2) or any successor regulation, that such statement has been made. The Company’s written statement to any Purchaser shall be delivered
to such Purchaser within ten (10) days of such Purchaser’s written request therefor. The Company’s obligation to furnish a written statement pursuant to this Section 12(s) shall continue notwithstanding the fact that a class of
the Company’s stock may be regularly traded on an established securities market, but only to the extent required under Section 897 of the Code. 
  

 17 

 (t) Compensation and Audit Committees. The Company shall, by amending its By-laws or otherwise,
establish and maintain a Compensation Committee of the Board of Directors (the “Compensation Committee”), which shall consist of four (4) directors, including each of the Purchaser Nominees, and an Audit Committee of the Board of
Directors (the “Audit Committee”), which shall consist of three (3) directors, at least one of whom shall be a Purchaser Nominee, provided, however, that no director elected to the Compensation Committee shall be an
officer of the Company. No compensation or other remuneration at an annual rate in excess of $150,000 shall be paid to, and no capital stock of the Company shall be issued or granted to, any director, officer or employee of, or any consultant or
adviser to, the Company or any of its subsidiaries, without the approval of the Compensation Committee. No employee stock option plan, employee stock purchase plan, employee restricted stock plan or other employee stock plan shall be established
without the approval of the Compensation Committee. The Audit Committee shall select (subject to the approval of the Board of Directors) and provide instructions to the Company’s auditors. 
 (u) Termination of Covenants. The covenants set forth in Section 12(s) shall terminate and be of no further force or effect as to each of the
Purchasers when such Purchaser no longer holds any shares of capital stock of the Company. All of the other covenants set forth in this Section 12 shall terminate and be of no further force or effect on the earlier of (i) the closing of
the Company’s first firm commitment underwritten public offering pursuant to an effective registration statement on Form S-1 (or its then equivalent) under the Securities Act of 1933, as amended, pursuant to which (A) the aggregate price
paid by the public for the purchase of Common Stock is at least $25,000,000, (B) the per-share price paid by the public for such Common Stock is at least $5.00 per share and (C) the Common Stock is listed on a nationally recognized United
States securities market, (ii) the sale of all or substantially all of the assets or business of the Company, by merger, sale of assets or otherwise, approved by the Board of Directors, which approval must include the approval of each of the
Purchaser Nominees, or (iii) as to each of the Purchasers, when such Purchaser owns less than 25% of the Preferred Shares owned by such Purchaser on the date hereof (equitably adjusted to reflect stock splits, stock dividends, combinations of
shares and the like). 
 13. Miscellaneous. 
 (a) All covenants and agreements contained in this Agreement by or on behalf of any of the parties hereto shall bind and inure to the benefit of the respective successors and assigns of the parties hereto (including
without limitation transferees of any Preferred Shares or Restricted Stock), whether so expressed or not, provided, however, that registration rights conferred herein on the holders of Preferred Shares or Restricted Stock shall only
inure to the benefit of a transferee of Preferred Shares or Restricted Stock if (i) there is transferred to such transferee at least 25% of the total shares of Restricted Stock then held by such transferor or (ii) such transferee is an
Affiliate of a party hereto. 
  

 18 

 (b) All notices, requests, consents and other communications hereunder shall be in writing and shall be
delivered in person, mailed by certified or registered mail, return receipt requested, or sent by telecopier or telex, addressed as follows: 
  

	 	•	 	 if to the Company, at the address of such party set forth in the Purchase Agreement; 

  

	 	•	 	 if to a Series A Purchaser, at the address of such party set forth in Schedule I hereto; 

  

	 	•	 	 if to a Series B Purchaser, at the address of such party set forth in Schedule III hereto; 

  

	 	•	 	 if to a Series C Purchaser, at the address of such party set forth in Schedule IV hereto; 

  

	 	•	 	 if to a Series D Purchaser, at the address of such party set forth in Schedule V hereto 

  

	 	•	 	 if to a Founder, at the address of such party set forth in Schedule II hereto; 

  

	 	•	 	 if to BMS, at the address set forth in the BMS License Agreement; 

  

	 	•	 	 if to any subsequent holder of Preferred Shares, Restricted Stock or Founders Stock, to it at such address as may have been furnished to the Company in writing by
such holder; 

 or, in any case, at such other address or addresses as shall have been furnished in writing to the Company (in the case of
a holder of Preferred Shares, Restricted Stock or Founders Stock) or to the holders of Preferred Shares, Restricted Stock or Founders Stock (in the case of the Company) in accordance with the provisions of this paragraph. 
 (c) This Agreement and any claim, controversy or cause of action (whether in contract, tort or otherwise) based upon, arising out of or relating to this
Agreement shall be governed by the substantive laws of the State of Delaware, without regard to its principles of conflicts of laws that would result in the application of any law other than the law of the State of Delaware. 
 (d) This Agreement may not be amended or modified, and no provision hereof may be waived, without
the written consent of the Company and the holders of at least two-thirds (66 2/3%) of the shares of
Restricted Stock (not including the Warrant Shares); provided, however, (1) that any amendment, modification or waiver adverse to the rights of the holders of Founders Stock may be effected only with the written consent of the
holders of a majority of outstanding Founders Stock so affected, and (2) any amendment, modification or waiver materially adverse to the registration rights provided by this Agreement as of the date first written above for the Preferred Shares
originally issued to BMS (the “BMS Preferred 

  

 19 

 
Shares”) or any outstanding BMS Originally Issued Common Shares may be effected only with the written consent of the holders of a majority of the
outstanding BMS Preferred Shares plus any outstanding BMS Originally Issued Common Shares so affected, or absent such consent, only if the Company grants in writing to the holders of the outstanding BMS Preferred Shares and any outstanding BMS
Originally Issued Common Shares so affected the same or substantially the same registration rights for such shares as provided by this Agreement as of the date hereof (taking into account any permitted amendments, modifications or waivers thereto).
It is understood and agreed that none of the following shall be deemed to be adverse to the holders of Founders Stock or the registrations rights provided by this Agreement for the BMS Preferred Shares and any BMS Originally Issued Common Shares
(i) an expansion of the definition of Restricted Stock, or (ii) modification of any time period(s) or percentage or dollar threshold(s), provided that any such modification(s) apply to all the Restricted Stock. The number of shares of
capital stock held by each party under this Agreement shall be determined on an as-converted to Common Stock basis. Notwithstanding anything herein to the contrary, immediately prior to the Subsequent Closing (as defined in the Purchase Agreement),
Schedule V hereto will be amended (without the need for any consent from any party hereto other than the Company) to list the name and address of any Additional Purchaser participating in the Subsequent Closing. 
 (e) This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one
and the same instrument. This Agreement may be executed by facsimile signatures. 
 (f) The obligations of the Company to register shares of
Restricted Stock and Founders Stock under Sections 4, 5 or 6, as the case may be, shall terminate on the seventh anniversary of the effective date of the registration statement covering the initial public offering of securities of the Company
under the Securities Act. 
 (g) If requested in writing by the Company and the underwriters for the initial underwritten public offering of
securities of the Company, each holder of Restricted Stock or Founders Stock who is a party to this Agreement shall not sell publicly, or otherwise transfer or dispose of, any shares of Restricted Stock, Founders Stock or any other shares of Common
Stock (other than shares of Restricted Stock, Founders Stock or other shares of Common Stock being registered in such offering), without the consent of such underwriters, for a period of not more than one hundred eighty (180) days following the
effective date of the registration statement relating to such offering (the “Lock-Up Period”); provided, however, that all persons entitled to registration rights with respect to shares of Common Stock who are not parties to
this Agreement, all other persons selling shares of Common Stock in such offering, all persons holding in excess of 1% of the capital stock of the Company on a fully diluted basis and all executive officers and directors of the Company shall also
have agreed to the same restrictions with such underwriters; and further provided that the Company shall use its reasonable best efforts to ensure that such market standoff agreements provide for periodic early releases of portions of the securities
subject to the restrictions set forth in this section upon the occurrence of certain specified events and in the event of any early release of such securities, all Purchasers will be released on a pro rata basis from such market standoff agreements.
Each holder of Restricted Stock or Founders Stock who is a party to this Agreement agrees that if (i) during the last seventeen (17) days of the Lock-Up Period, the Company issues an earnings release or material news or a material event
relating to the Company occurs, or (ii) prior to the expiration of 

  

 20 

 
the Lock-Up Period, the Company announces that it will release earnings results during the sixteen (16) day period beginning on the last day of the
Lock-Up Period, the Lock-Up Period shall be automatically extended until the expiration of the eighteen (18) day period beginning on the issuance of the earnings release or the occurrence of the material news or material event. 
 (h) Notwithstanding the provisions of Section 7(a), the Company’s obligation to file a registration statement, or cause such registration
statement to become and remain effective, shall be suspended for a period not to exceed one hundred eighty (180) days in any 24-month period if there exists at the time material non-public information relating to the Company which, in the
reasonable opinion of the Company, should not be disclosed. 
 (i) The Company shall not grant to any third party any registration rights
more favorable than or inconsistent with any of those contained herein, so long as any of the registration rights under this Agreement remains in effect. 
 (j) If any provision of this Agreement shall be held to be illegal, invalid or unenforceable, such illegality, invalidity or unenforceability shall attach only to such provision and shall not in any manner affect or
render illegal, invalid or unenforceable any other provision of this Agreement, and this Agreement shall be carried out as if any such illegal, invalid or unenforceable provision were not contained herein. 
 14. Termination of Prior Agreement. Notwithstanding anything to the contrary contained in
the Prior Agreement, the undersigned Company, holders of at least two-thirds (66 2/3%) of the outstanding
shares of Restricted Stock (as defined in the Prior Agreement) hereby agree, acting in accordance with Section 13(d) of the Prior Agreement, that the Prior Agreement is hereby amended and restated in its entirety, renamed and superseded by the
terms and conditions of this Agreement. 
 [REMAINDER OF PAGE LEFT INTENTIONALLY BLANK] 
  

 21 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	COMPANY:
	
	ELIXIR PHARMACEUTICALS, INC.
		
	By:	 	 /s/ William K. Heiden

	Name:	 	William K. Heiden
	Title:	 	President and Chief Executive Officer

  

 Signature Page to Second Amended and Restated Stockholder Rights Agreement 

							
		  		  		  	Schedule I
		  		  		  	to Second Amended and
		  		  		  	Restated Stockholder Rights
		  		  		  	Agreement

 Series A Purchasers 
 ARCH Venture Fund V, L.P. 
 8725 W. Higgins Road, 
 Suite 290 
 Chicago, IL 60631 
 ARCH V Entrepreneurs Fund, L.P. 
 8725 W. Higgins Road, 
 Suite 290 
 Chicago, IL 60631 
 MPM BioVentures II, L.P

 The John Hancock Tower 
 200 Clarendon Street 
 54th Floor 

 Boston, MA 02116 
 MPM BioVentures II-QP, L.P. 
 The John Hancock Tower 
 200 Clarendon Street 
 54th Floor 

 Boston, MA 02116 
 MPM BioVentures Gmbh & CO.
Parallel – 
 Beteiligungs KG 
 The John Hancock Tower

 200 Clarendon Street 
 54th Floor 
 Boston, MA
02116 
 MPM Asset Management Investors 2001 LLC 
 The John
Hancock Tower 
 200 Clarendon Street 
 54th Floor 
 Boston, MA
02116 
 mRNA Fund L.P. 
 222 Berkeley Street, 
 Suite 1650 
 Boston, MA 02116 

 Omega Fund II, L.P. 
 c/o
International Private Equity Services Limited 
 P.O. Box 431, Alexander House. 13-15 Victoria Road 
 St. Peter Port, Guernsey GY1 3ZD, Channel Islands 
 United Kingdom 

Oxford Bioscience Partners III L.P. 
 222 Berkeley Street, 
 Suite 1650 
 Boston, MA 02116 
 Oxford Bioscience Partners (Bermuda) III Limited Partnership 
 222 Berkeley
Street, 
 Suite 1650 
 Boston, MA 02116 
 Oxford Bioscience Partners (Adjunct) III L.P. 
 222 Berkeley Street,

 Suite 1650 
 Boston, MA 02116 
 Trustees of Boston University 
 108 Bay State Road 
 Boston, MA 02215 

							
		  		  		  	Schedule II
		  		  		  	to Second Amended and
		  		  		  	Restated Stockholder Rights
		  		  		  	Agreement

 Holders of Founders Stock 
 Leonard P. Guarente, PhD 
 MIT 
 31 Ames Street 
 Bldg 68, Room 280 
 Cambridge, MA 02139

 Cynthia Kenyon, PhD 
 55 Los Pinos Spur 
 Nicasio, CA 94946-9759 
 Cindy Bayley, PhD 
 P.O. Box 5237 
 Norwell, MA 02061 
 Louis Kunkel 
 Division of Genetics, Enders 5 
 Children’s Hospital 
 300 Longwood Ave. 
 Boston, MA 02115 
 Annibale Puca 
 Via San pasquale 24 
 80100 Napoli 
 Italy 
 The Boston Foundation 
 75 Arlington Street 
 Boston, MA 02116 

							
		  		  		  	Schedule III
		  		  		  	to Second Amended and
		  		  		  	Restated Stockholder Rights
		  		  		  	Agreement

 Series B Purchasers 
 Larry Abrams 
 101 Westcott Street, Apt 1601 
 Houston, TX 77007 
 AHI/ELX Associates, LLC 
 c/o Angel Healthcare Investors, LLC 
 One Gateway Center, Suite 902 
 Newton, MA 02458 
 Prince Ahmad Bin Khalid Al-Saud 
 21650 Oxford Street, 
 Suite 100 
 Woodland Hills, CA 91367-4907 
 Bristol-Myers Squibb Company 
 P.O. Box 4000 
 Route 206 & Province Line Road 
 Princeton, NJ 08543-4000 
 ARCH Venture Fund V, L.P. 
 8725 W. Higgins Road, 
 Suite 290 
 Chicago, IL 60631 
 ARCH V Entrepreneurs Fund, L.P. 
 8725 W. Higgins Road, 
 Suite 290 
 Chicago, IL 60631 
 Franklin M. Berger 
 470 Park Avenue South 
 9th Floor North 
 New York, NY 10016

 Trustees of Boston University 
 108 Bay State Road 

Boston, MA 02215 

 Wellington Chen and Josephine Chen, JTWROS 
 Attn: Josephine Chen 
 17869 Tramonto Drive 
 Pacific Palisades, CA 90272 
 DeA Capital SpA (formerly Cdb Web Tech SpA) 
 Via Borgonuovo, 24 
 20121 Milano, Italy 
 Healthcare Focus Fund, L.P. 
 8725 W. Higgins Road, 
 Suite 290 
 Chicago, IL 60631 
 INDALCO S.A. 
 Attention: Frank Walters 
 c/o Moore Stephens Services, SAM 
 L’Estoril, Bloc C 
 31 Avenue Princesse Grace 
 MC 98000 Monaco 
 MPM BioVentures II, L.P. 
 The John Hancock Tower 
 200 Clarendon Street 
 54th Floor 
 Boston, MA 02116 
 MPM BioVentures II-QP, L.P. 
 The John Hancock Tower 
 200 Clarendon Street 
 54th Floor 
 Boston, MA 02116 
 MPM BioVentures Gmbh & Co. Parallel – 
 Beteiligungs KG

 The John Hancock Tower 
 200 Clarendon Street 
 54th Floor 

 Boston, MA 02116 
 MPM Asset Management Investors 2001 LLC

 The John Hancock Tower 
 200 Clarendon Street 
 54th Floor 

 Boston, MA 02116 

 mRNA Fund L.P. 
 222 Berkeley
Street 
 Boston, MA 02116 
 MunMun International Ltd.

 c/o Saudi Fal Group 
 PO Box 4900 
 Riyadh, Saudi Arabia 
 NADFA Ltd. 
 PO Box 10071 
 Riyadh 11433 
 Kingdom of Saudi Arabia 
 Oxford Bioscience Partners III L.P. 
 222 Berkeley Street 
 Boston, MA 02116 
 Oxford Bioscience Partners (Adjunct) III L.P. 
 222 Berkeley Street

 Boston, MA 02116 
 Oxford Bioscience Partners (Bermuda) III

 Limited Partnership 
 222 Berkeley Street 
 Boston, MA 02116 
 Saudi Venture Development Company Ltd. 
 PO Box 9175 
 Riyadh 11413 
 Saudi Arabia 
 Omega Fund II, L.P. 
 c/o International Private Equity Services Limited 
 P.O. Box 431, Alexander
House. 13-15 Victoria Road 
 St. Peter Port, Guernsey GY1 3ZD, Channel Islands 
 United Kingdom 
 Teachers Insurance and Annuity Association of America 
 730 3rd Avenue

 Attn: Holly Holtz (Securities Division) 
 New York, NY
10017 

 Tako Ventures, LLC 
 c/o
Steven Fink 
 CEO Lawrence Investments 
 3610 Serra Road

 Malibu, CA 90265 
 Ziad A. Al-Sudiary 
 PO Box 10071 
 Riyadh 11433 
 Kingdom of Saudi Arabia 

							
		  		  		  	Schedule IV
		  		  		  	to Second Amended and
		  		  		  	Restated Stockholder Rights
		  		  		  	Agreement

 Series C Purchasers 
 Larry Abrams 
 101 Westcott Street, Apt 1601 
 Houston, TX 77007 
 AHI/ELX Associates, LLC 
 c/o Angel Healthcare Investors, LLC 
 One Gateway Center, Suite 902 
 Newton, MA 02458 
 Prince Ahmad Bin Khalid Al-Saud 
 21650 Oxford Street, 
 Suite 100 
 Woodland Hills, CA 91367-4907 
 Ziad A. Al-Sudiary 
 PO Box 10071 
 Riyadh 11433 
 Kingdom of Saudi Arabia 
 ARCH Venture Fund V, L.P. 
 8725 W. Higgins Road, 
 Suite 290 
 Chicago, IL 60631 
 ARCH V Entrepreneurs Fund, L.P. 
 8725 W. Higgins Road, 
 Suite 290 
 Chicago, IL 60631 
 Franklin M. Berger 
 470 Park Avenue South 
 9th Floor North 
 New York, NY 10016

 CDIB BioScience Ventures I, Inc. 
 9191 Towne Centre Drive, Suite 575 
 San Diego, CA 92122 
 fax : 858-552-6811 
 Attn: Chin-tuck Lee 
 9F-1,
No. 205, Sec 3, Peishin Road, Hsintien City, Taipei, Taiwan 
 fax : 886-2-8913-1955 
 Attn: Cynthia Hsiah 
 Wellington Chen and Josephine Chen, JTWROS 
 Attn: Josephine Chen 
 17869 Tramonto Drive 
 Pacific Palisades, CA 90272 
 DeA Capital SpA (formerly Cdb Web Tech SpA)

 Via Borgonuovo, 24 
 20121 Milano, Italy 
 Healthcare Focus Fund, L.P. 
 8725 W. Higgins Road, 
 Suite 290 
 Chicago, IL 60631 
 INDALCO S.A. 
 Attention: Frank Walters 
 c/o Moore Stephens Services, SAM 
 L’Estoril, Bloc C 
 31 Avenue Princesse Grace 
 MC 98000 Monaco 
 JAFCO Life Science No.1 Investment Enterprise Partnership 
 c/o JAFCO Co.,
Ltd. 
 1-8-2, Marunouchi, Chiyoda-ku, Tokyo 100-005 Japan 
 Attn:
Miki Murata, Assistant Manager, Life Science Investment Department 
 Paul B. Kopperl 1997 Trust (formerly Paul B. Kopperl) 
 6 Deer Hill Road 
 P.O. Box 301 
 West Stockbridge, MA 01266 
 MMM Ltd. 
 PO Box 10071 
 Riyadh 11433 
 Kingdom of Saudi Arabia 

 MPM BioVentures II, L.P. 
 The John Hancock Tower 
 200 Clarendon Street 
 54th Floor 

 Boston, MA 02116 
 MPM BioVentures II-QP, L.P. 
 The John Hancock Tower 
 200 Clarendon Street 
 54th Floor 

 Boston, MA 02116 
 MPM BioVentures GMBH & Co.
Parallel-Beteiligungs KG 
 The John Hancock Tower 
 200 Clarendon
Street 
 54th Floor 
 Boston, MA 02116 
 MPM Asset Management
Investors 2001 LLC 
 The John Hancock Tower 
 200 Clarendon
Street 
 54th Floor 
 Boston, MA 02116 
 MunMun International
Ltd. 
 c/o Saudi Fal Group 
 PO Box 4900 
 Riyadh, Saudi Arabia 
 NADFA Ltd. 
 PO Box 10071 
 Riyadh 11433 
 Kingdom of Saudi Arabia 
 Omega Fund II, L.P. 
 c/o International Private Equity Services Limited 
 P.O. Box 431, Alexander
House. 13-15 Victoria Road 
 St. Peter Port, Guernsey GY1 3ZD, Channel Islands 
 United Kingdom 
 Oxford Bioscience Partners III L.P. 
 222 Berkeley Street, Suite 1650 
 Boston, MA 02116 

 Oxford Bioscience Partners (Bermuda) III Limited Partnership 
 222 Berkeley Street, Suite 1650 
 Boston, MA 02116 
 Oxford Bioscience Partners (Adjunct) III L.P. 
 222 Berkeley Street, Suite
1650 
 Boston, MA 02116 
 mRNA Fund L.P. 
 222 Berkeley Street, Suite 1650 
 Boston, MA 02116 
 Philip R. Reilly 
 145 Monument ST. 
 Concord, MA 01742 
 Saudi Venture Development Company Ltd. 
 PO Box 9175 
 Riyadh 11413 
 Saudi Arabia 
 Taiwan Global Biofund 
 4F, 51, Sec.2, Chung Ching South Rd., Taipei, Taiwan 
 Trustees of Boston
University 
 108 Bay State Road 
 Boston, MA 02215 
 Bonnie D. Zell 
 1420 Terry Ave., Unit 2301 
 Seattle, WA 98101 

							
		  		  		  	Schedule V
		  		  		  	to Second Amended and
		  		  		  	Restated Stockholder Rights
		  		  		  	Agreement

 Series D Purchasers 
 Larry Abrams 
 101 Westcott Street, Apt 1601 
 Houston, TX 77007 
 AHI/ELX Associates, LLC 
 c/o Angel Healthcare Investors, LLC 
 One Gateway Center, Suite 902 
 Newton, MA 02458 
 Prince Ahmad Bin Khalid Al-Saud 
 21650 Oxford Street, 
 Suite 100 
 Woodland Hills, CA 91367-4907 
 ARCH Venture Fund V, L.P. 
 8725 W. Higgins Road, 
 Suite 290 
 Chicago, IL 60631 
 ARCH V Entrepreneurs Fund, L.P. 
 8725 W. Higgins Road, 
 Suite 290 
 Chicago, IL 60631 
 Franklin M. Berger 
 470 Park Avenue South 
 9th Floor North 
 New York, NY 10016

 CDIB BioScience Ventures I, Inc. 
 9191 Towne Centre Drive,
Suite 575 
 San Diego, CA 92122 
 fax : 858-552-6811 

Attn: Chin-tuck Lee 
 9F-1, No. 205, Sec 3, Peishin Road, Hsintien
City, Taipei, Taiwan 
 fax : 886-2-8913-1955 
 Attn: Cynthia
Hsiah 

 Wellington Chen and Josephine Chen, JTWROS 
 Attn: Josephine Chen 
 17869 Tramonto Drive 
 Pacific Palisades, CA 90272 
 DeA Capital (formerly Cdb Web Tech SpA) 
 Via Borgonuovo, 24 
 20121 Milano, Italy 
 Healthcare Focus Fund, L.P. 
 8725 W. Higgins Road, 
 Suite 290 
 Chicago, IL 60631 
 Paul B. Kopperl 1997 Trust (formerly Paul B. Kopperl) 
 6 Deer Hill Road

 P.O. Box 301 
 West Stockbridge, MA 01266 
 MPM BioVentures II, L.P. 
 The John Hancock Tower 
 200 Clarendon Street 
 54th Floor 
 Boston, MA 02116 
 MPM BioVentures II-QP, L.P. 
 The John Hancock Tower 
 200 Clarendon Street 
 54th Floor 
 Boston, MA 02116 
 MPM BioVentures GMBH & Co. Parallel-Beteiligungs KG 
 The John
Hancock Tower 
 200 Clarendon Street 
 54th Floor 
 Boston, MA
02116 
 MPM Asset Management Investors 2001 LLC 
 The John
Hancock Tower 
 200 Clarendon Street 
 54th Floor 
 Boston, MA
02116 

 MPM BioVentures Strategic Fund, L.P. 
 The John Hancock Tower 
 200 Clarendon Street 
 54th Floor 

 Boston, MA 02116 
 MPM Bio IV NVS Strategic Fund, L.P.

 The John Hancock Tower 
 200 Clarendon Street 
 54th Floor 

 Boston, MA 02116 
 mRNA Fund L.P. 
 222 Berkeley Street, Suite 1650 
 Boston, MA 02116 
 MunMun International Ltd. 
 c/o Saudi Fal Group 
 PO Box 4900 
 Riyadh, Saudi Arabia 
 Omega Fund II, L.P. 
 c/o International Private Equity Services Limited

 P.O. Box 431, Alexander House. 13-15 Victoria Road 
 St. Peter
Port, Guernsey GY1 3ZD, Channel Islands 
 United Kingdom 
 Oxford Bioscience Partners III L.P. 
 222 Berkeley Street, Suite 1650 
 Boston, MA 02116 
 Oxford Bioscience Partners (Bermuda) III Limited Partnership 
 222 Berkeley Street, Suite 1650 
 Boston, MA 02116 
 Oxford Bioscience Partners (Adjunct) III L.P. 
 222 Berkeley Street, Suite
1650 
 Boston, MA 02116 
 Philip R. Reilly 
 145 Monument ST. 
 Concord, MA 01742 
 Physic Ventures, L.P. 
 200 California Street, 5th Floor 
 San Francisco, CA 94111 

 Saudi Venture Development Company Ltd. 
 PO Box 9175 
 Riyadh 11413 
 Saudi Arabia 
 Taiwan Global Biofund 
 4F, 51, Sec.2,
Chung Ching South Rd., Taipei, Taiwan 
 Teachers Insurance and Annuity Association of America 
 730 3rd Avenue

 Attn: Holly Holtz (Securities Division) 
 New York, NY
10017 
 Trustees of Boston University 
 108 Bay State Road

 Boston, MA 02215 
 Bonnie D. Zell 
 1420 Terry Ave., Unit 2301 
 Seattle, WA 98101 

							
		  		  		  	Exhibit A
		  		  		  	to Second Amended and
		  		  		  	Restated Stockholder Rights
		  		  		  	Agreement

 Instrument of Accession 
 Reference is made to that certain Second Amended and Restated Stockholder Rights Agreement dated as of September 4, 2007, a copy of which is
attached hereto (as amended and in effect from time to time, the “Stockholder Rights Agreement”), among Elixir Pharmaceuticals, Inc. (the “Company”) and the Founders and the Purchasers (as defined therein).

 The undersigned,
                                        ,
in order to become the owner or holder of
                                        
shares of Restricted Stock (as defined in the Stockholder Rights Agreement) or securities convertible into or exchangeable for Restricted Stock (the “Securities”) of the Company, hereby agrees that by execution hereof the
undersigned is a Purchaser party to the Stockholder Rights Agreement subject to all of the restrictions and conditions applicable to Purchasers set forth in such Stockholder Rights Agreement, and all of the Securities purchased by the undersigned in
connection herewith (and any and all shares of stock of the Company issued in respect thereof) are subject to all the restrictions and conditions applicable to Restricted Stock as set forth in the Stockholder Rights Agreement. This Instrument of
Accession shall take effect and shall become a part of said Stockholder Rights Agreement immediately upon execution. 
 Executed as of the
date set forth below under the laws of the State of Delaware. 
  

											
		 		 		 	Signature:	 	  
	 	
		 		 		 	Address:	 		 	
						
		 		 		 	Date:	 	  
	 	
					
	Accepted:	 		 		 		 	
					
	ELIXIR PHARMACEUTICALS, INC.	 		 		 		 	
						
	By:	 	  
	 		 		 		 	
	Name:	 		 		 		 		 	
	Title:	 		 		 		 		 	
	Date:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}]]